fluconazole has been researched along with Benign Neoplasms in 118 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy." | 9.08 | Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996) |
| "We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0." | 9.08 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998) |
| "An open, prospective, randomized pilot study was performed to assess the efficacy and safety of oral fluconazole 3 mg/kg once daily compared with oral nystatin 50,000 units/kg/day in four divided doses in preventing candida infections in 50 children undergoing remission induction or consolidation therapy for cancer." | 9.08 | Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. ( Groll, AH; Just-Nuebling, G; Kornhuber, B; Kurz, M; Mueller, C; Nowak-Goettl, U; Schwabe, D; Shah, PM, 1997) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 8.90 | Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 8.83 | Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006) |
| "Systemic Candida infections are a major cause of infectious morbidity and mortality during chemotherapy-induced neutropenia." | 7.77 | The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. ( Wingard, JR, 1992) |
| "Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia." | 7.73 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006) |
| " and 10 non-Candida yeasts) recovered from 169 surgical, neonatal, critically ill intensive care unit patients (ICU), and cancer patients (mixed patient population) to amphotericin B (AmB), fluconazole (FLU), 5-flucytosine (5-FC), itraconazole (ITRA), ketoconazole (KETO), miconazole (MICO), and nystatin (NYS), in order to correlate in-vitro resistance to fluconazole with the outcome of fungemia." | 7.70 | Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? ( Bille, J; Hanzen, J; Kovacicova, G; Krcmery, V; Krupova, Y; Lamosova, M; Liskova, A; Lovaszova, M; Macekova, L; Milosovic, P; Obertik, T; Purgelova, A; Roidova, A; Szovenyiova, Z; Trupl, J, 2000) |
| "The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression." | 7.68 | Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. ( Blahova, M; Fuchsberger, P; Hornikova, M; Koza, I; Krcméry, V; Mardiak, J; Migom, C; Savko, V; Spanik, S; Sufliarsky, J, 1991) |
| "Fluconazole is a triazole antifungal agent which is now an established part of therapy in patients with immune deficiencies." | 6.39 | Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. ( Barradell, LB; Goa, KL, 1995) |
| "Post hoc analysis of patient-level efficacy and safety data from six studies of anidulafungin (with similar protocols/endpoints) in adults with IC/candidemia summarized by past or recent diagnosis of solid tumors." | 5.12 | Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies. ( Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL, 2021) |
| "A total of 317 neutropenic patients (<500 cells/mm3) with persistent or recrudescent fever despite 4 or more days of antibacterial therapy were randomly assigned to receive either fluconazole (400 mg intravenously once daily) or amphotericin B (0." | 5.09 | A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. ( Hathorn, JW; Schiller, GJ; Schuster, MG; Territo, MC; Winston, DJ, 2000) |
| "Amphotericin B, despite its intrinsic servere toxicity, is the most commonly used empirical antifungal therapy in cancer patients with unexplained fever not responding to empirical antibacterial therapy." | 5.08 | Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial. ( Caselli, D; Castagnola, E; Congiu, M; Fanci, R; Garaventa, A; Giacchino, M; Menichetti, F; Moroni, C; Rossi, MR; Van Lint, MT; Viscoli, C, 1996) |
| "We randomly assigned 106 patients with absolute neutropenia (< or = 500 cells microL) and persistent fever of undetermined origin (> 38 degrees C) despite 1 week of broad-spectrum antibiotic therapy to receive either fluconazole 400 mg orally daily or amphotericin B 0." | 5.08 | A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. ( Aziz, Z; Khan, S; Malik, IA; Moid, I; Suleman, M, 1998) |
| "An open, prospective, randomized pilot study was performed to assess the efficacy and safety of oral fluconazole 3 mg/kg once daily compared with oral nystatin 50,000 units/kg/day in four divided doses in preventing candida infections in 50 children undergoing remission induction or consolidation therapy for cancer." | 5.08 | Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. ( Groll, AH; Just-Nuebling, G; Kornhuber, B; Kurz, M; Mueller, C; Nowak-Goettl, U; Schwabe, D; Shah, PM, 1997) |
| "To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia." | 4.90 | Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gøtzsche, PC; Johansen, HK, 2014) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 4.90 | Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. ( Dalbøge, CS; Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2014) |
| "To compare the benefits and harms of voriconazole with those of amphotericin B and fluconazole when used for prevention or treatment of invasive fungal infections in cancer patients with neutropenia." | 4.83 | Voriconazole versus amphotericin B in cancer patients with neutropenia. ( Gøtzsche, PC; Johansen, HK; Jørgensen, KJ, 2006) |
| "To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia." | 4.81 | Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gøtzsche, PC; Johansen, HK, 2002) |
| "To compare the effect of fluconazole and amphotericin B on morbidity and mortality in patients with cancer complicated by neutropenia." | 4.80 | Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. ( Gotzsche, PC; Johansen, HK, 2000) |
| " Early studies suggest that a new acyclic nucleoside, ganciclovir, has some effect in the treatment of cytomegalovirus infections, but its precise use in patients with cancer has not been fully established." | 4.78 | New drugs for infections in patients with cancer. ( Hughes, WT, 1992) |
| " Since all fluconazole resistance isolates were obtained from candidemia, we recommend amphotericin B as the first line therapy for this potentially fatal infection." | 4.31 | A 3-year study of ( Abastabar, M; Badiee, P; Haghani, I; Mohammadi, R; Morovati, H; Noorbakhsh, M; Sharifi, M, 2023) |
| "Fluconazole is recommended as first-line treatment in invasive candidiasis in children and infants." | 3.80 | Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children. ( Alffenaar, JW; Kosterink, JG; Pereboom, M; Schölvinck, EH; van den Heuvel, ER; van der Elst, KC, 2014) |
| "Systemic Candida infections are a major cause of infectious morbidity and mortality during chemotherapy-induced neutropenia." | 3.77 | The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. ( Wingard, JR, 1992) |
| "Several clinical trials have demonstrated the efficacy of fluconazole as empiric antifungal therapy in cancer patients with fever and neutropenia." | 3.73 | Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia. ( Bates, DW; Kumar, RN; Peterson, JF; Seger, DL; Yu, DT, 2006) |
| " We describe the unanticipated problems we encountered in collecting data for a meta-analysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia." | 3.70 | Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. ( Gotzsche, PC; Johansen, HK, 1999) |
| " and 10 non-Candida yeasts) recovered from 169 surgical, neonatal, critically ill intensive care unit patients (ICU), and cancer patients (mixed patient population) to amphotericin B (AmB), fluconazole (FLU), 5-flucytosine (5-FC), itraconazole (ITRA), ketoconazole (KETO), miconazole (MICO), and nystatin (NYS), in order to correlate in-vitro resistance to fluconazole with the outcome of fungemia." | 3.70 | Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia? ( Bille, J; Hanzen, J; Kovacicova, G; Krcmery, V; Krupova, Y; Lamosova, M; Liskova, A; Lovaszova, M; Macekova, L; Milosovic, P; Obertik, T; Purgelova, A; Roidova, A; Szovenyiova, Z; Trupl, J, 2000) |
| "The efficacy and safety of fluconazole, a new triazole antifungal agent, was evaluated in 24 patients with neutropenia due to cytotoxic anticancer chemotherapy with polyfactorial immunodepression." | 3.68 | Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients. ( Blahova, M; Fuchsberger, P; Hornikova, M; Koza, I; Krcméry, V; Mardiak, J; Migom, C; Savko, V; Spanik, S; Sufliarsky, J, 1991) |
| " Pharmacokinetic profiles for micafungin on days 1 and 7 were similar." | 2.71 | Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. ( Buell, D; Cagnoni, P; Chao, N; Devine, S; Facklam, D; Hiemenz, J; Keirns, J; Lau, W; Simpson, D, 2005) |
| "Both cancer centers differed in prophylactic antibiotic policies." | 2.69 | Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome. ( Foltinova, A; Kaiserova, E; Kiskova, M; Kovacicova, G; Krchnakova, A; Krcmery, V; Krupova, I; Kunova, A; Trupl, J; West, D, 1998) |
| " Adverse events, plasma levels, and clinical response were examined." | 2.68 | Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections. ( Anaissie, EJ; Bodey, GP; Bosso, J; Huls, C; Karl, C; Kontoyiannis, DP; Prince, RA; Vartivarian, SE, 1995) |
| "Fluconazole was found to be effective for preventing systemic fungal infections in neutropenic patients with cancer." | 2.68 | Prophylactic use of fluconazole in neutropenic cancer patients. ( Haznedar, R; Senol, E; Yamaç, K, 1995) |
| "Fluconazole was evaluated prospectively in 173 children aged between 4 months and 16 years in whom conventional antifungal therapy was ineffective or contraindicated." | 2.67 | Fluconazole treatment of children with severe fungal infections not treatable with conventional agents. ( Fasano, C; Gibbs, D; O'Keeffe, J, 1994) |
| "Fluconazole has proved to be effective in treating oropharyngeal and esophageal candidiasis in immunocompromised patients." | 2.67 | Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome. ( Akalin, HE; Akova, M; Aslan, S; Hayran, M; Kansu, E; Tekuzman, G; Telatar, H; Uzun, O, 1994) |
| "Opportunistic mycoses have emerged as important causes for morbidity and mortality in pediatric cancer patients, particularly in those with intensively treated hematological malignancies, allogeneic hematopoetic stem cell transplantation, and aplastic anemia." | 2.41 | [Prevention of fungal infections in children and adolescents with cancer]. ( Groll, AH; Müller, FM; Ritter, J, 2001) |
| "Patients with cancer complicated by neutropenia." | 2.40 | Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. ( Gøtzsche, PC; Johansen, HK, 1997) |
| "krusei fungemia from our cancer institute." | 2.40 | Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review. ( Grausova, S; Grey, E; Krcmery, V; Krupova, I; Kunova, A; Mateicka, F; Pichnova, E; Sabo, A; Spanik, S; Trupl, J, 1999) |
| "Invasive fungal infections are one of the leading causes of morbidity and mortality in cancer patients." | 2.40 | Antifungal treatment in patients with cancer. ( Castagnola, E; Machetti, M; Viscoli, C, 1997) |
| "All three infections appeared in cancer patients presented with fungaemia, one additionally with meningitis." | 2.40 | Invasive infections due to Clavispora lusitaniae. ( Grausova, S; Hanzen, J; Krcmery, V; Kunova, A; Mateicka, F, 1999) |
| " However, bioavailability of itraconazole is reduced in patients with raised gastric pH and no i." | 2.39 | [Prophylaxis against mycoses in neutropenic patients]. ( Arning, M; Aul, C, 1994) |
| "Fluconazole has been shown effective as prophylaxis of candidosis including in patients undergoing bone marrow transplantation as well as in treatment of oropharyngeal candidosis and for candidaemia occurring in non-neutropenic patients." | 2.39 | [Therapy of systemic candidiasis]. ( Meunier, F, 1994) |
| "Fluconazole is a triazole antifungal agent which is now an established part of therapy in patients with immune deficiencies." | 2.39 | Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients. ( Barradell, LB; Goa, KL, 1995) |
| "Candidemia is a life-threatening invasive fungal infection in immunocompromised patients." | 1.91 | Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt. ( Abdel-Hamid, RM; Abdelfattah, NE; El-Mahallawy, HA; Wassef, MA, 2023) |
| " Nonetheless, there is a lack in pharmacokinetics information for this population, and dosing criteria may vary between healthcare centers." | 1.91 | Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program. ( Arriaga-García, FJ; Medellín-Garibay, SE; Milán-Segovia, RDC; Pérez-González, LF; Rodríguez-Báez, AS; Romano-Moreno, S; Velarde-Salcedo, R, 2023) |
| "Patients with advanced cancer are prone to develop different opportunistic oral infection due to anti-cancer treatment or the malignancies themselves." | 1.91 | Identification and susceptibility testing of oral candidiasis in advanced cancer patients. ( Enersen, M; Fjeld, KG; Gay, CL; Herlofson, BB; Hove, LH; Kristoffersen, AK; Lerdal, A; Monsen, RE; Nordgarden, H; Tollisen, A, 2023) |
| "Resistance to azole drugs has been observed in candidiasis due to their long-term use and poor response to treatment." | 1.72 | The evaluation of the overexpression of the ERG-11, MDR-1, CDR-1, and CDR-2 genes in fluconazole-resistant Candida albicans isolated from Ahvazian cancer patients with oral candidiasis. ( Dehghan, P; Fatahinia, M; Maheronnaghsh, M; Teimoori, A, 2022) |
| "Currently, cancer patients with microbial infection are a severe challenge in clinical treatment." | 1.72 | Synthesis of Hemiprotonic Phenanthroline-Phenanthroline ( Cui, Z; Fu, A; Fu, C; Keerthiga, R; Li, X; Tong, T; Yang, X; Zhang, Y; Zhao, Z, 2022) |
| "in the saliva of cancer patients." | 1.56 | Prevalence and susceptibility profile of Candida spp. isolated from patients in cancer therapy. ( Andrade, D; Bim, FL; Macedo, AP; Oliveira, VC; Sousa, ÁFL; Souza E Silva, VC; Watanabe, E, 2020) |
| "Oral thrush is a common fungal infection of the mouth experienced by palliative medicine and hospice patients who have advanced cancer." | 1.46 | Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients. ( Cheema, B; Cothren, B; Davis, M; Gamier, P; Gopal, S; Lagman, R; LeGrand, S; Parala, A; Rybicki, L; Walsh, D, 2017) |
| "The clinical context of underlying malignancy and hospitalization in ICU may be relevant to the initial management of candidemia." | 1.46 | The risk and clinical outcome of candidemia depending on underlying malignancy. ( Bretagne, S; Desnos-Ollivier, M; Dromer, F; Lortholary, O; Renaudat, C; Sitbon, K, 2017) |
| "Coccidioidomycosis is a common infection in the desert southwestern USA; approximately 3 % of healthy persons in Arizona alone become infected annually." | 1.43 | Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature. ( Berg, Z; Blair, JE; Fitterer, C; Halfdanarson, TR; Kusne, S; Orenstein, R; Seville, MT; Vikram, HR, 2016) |
| "Cancer was the most common underlying disease (n = 127, 72." | 1.42 | Epidemiology and prognostic factors of candidemia in elderly patients. ( Lai, CC; Lin, HL; Liu, WL; Tang, HJ, 2015) |
| "Malignancy was independently associated with the development of candidemia by non-albicans Candida species (odds ratio 3." | 1.40 | Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia. ( Al Amri, AF; Al Harbi, MI; Al Thaqafi, AH; Farahat, FM; Perfect, JR, 2014) |
| "Posaconazole was associated with an overall cost savings (range = $Can1,765 to $Can4,505) in all of the scenarios evaluated." | 1.37 | Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis. ( Dranitsaris, G; Khoury, H, 2011) |
| "Candidaemia in cancer patients is associated with increasing fluconazole resistance." | 1.36 | Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death. ( Chen, SC; Ellis, DH; Marriott, D; Morrissey, CO; Nguyen, Q; Slavin, MA; Sorrell, TC; Thursky, KA, 2010) |
| "Oral cheek mucosal specimens from 52 cancer patients receiving chemotherapy were cultured on CHROMagar Candida plates for Candida identification." | 1.35 | Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China. ( Lafleur, MD; Qi, C; Qi, QG; Sun, J, 2009) |
| "The extent of potential pharmacokinetic drug-drug interactions affecting anticancer agents disposition has not been specifically investigated." | 1.35 | Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients. ( Beretz, L; Bergerat, JP; Lemachatti, J; Levêque, D, 2009) |
| "Hematologic malignancy and neutropenia were significantly more frequent in children than in neonates and adults." | 1.35 | Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients. ( Blyth, CC; Chen, SC; Ellis, D; Marriott, D; Meyer, W; Nguyen, Q; Serena, C; Slavin, MA; Sorrell, TC, 2009) |
| "Fluconazole was used in 48% of the treatment episodes, amphotericin B in 46%, itraconazole in 4." | 1.34 | Drug-drug interactions with systemic antifungals in clinical practice. ( Abouelfath, A; Depont, F; Dupon, M; Dutronc, H; Galpérine, T; Giauque, E; Hébert, G; Moore, N; Ragnaud, JM; Valentino, R; Vargas, F, 2007) |
| "Cryptococcosis is not rare in HIV-negative patients." | 1.33 | Cryptococcosis in human immunodeficiency virus-negative patients. ( Kiertiburanakul, S; Pracharktam, R; Sungkanuparph, S; Wirojtananugoon, S, 2006) |
| "Anderson Cancer Center (1998-2002)." | 1.32 | High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study. ( Kontoyiannis, DP; Rolston, KV; Torres, HA, 2004) |
| "Candidemia cases in cancer patients from 1998 to 2001 (n = 144) were analyzed retrospectively along with their in vitro susceptibility to amphotericin B, fluconazole, and itraconazole (National Committee for Clinical and Laboratory Standards M27-A method)." | 1.32 | Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. ( Antoniadou, A; Bodey, GP; Han, XY; Kontoyiannis, DP; Lewis, RE; Raad, II; Rolston, KV; Safdar, A; Tarrand, JP; Thornby, J; Torres, HA, 2003) |
| "This study of patients with advanced cancer has demonstrated a high incidence of oral colonization with non-C." | 1.32 | High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. ( Al, MA; Bagg, J; Baxter, W; Coleman, D; Jackson, MS; Lewis, MA; McEndrick, S; McHugh, S; Sweeney, MP, 2003) |
| "Fluconazole was effective as a single agent in 3 patients with solid tumors." | 1.31 | Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. ( Hachem, R; Minari, A; Raad, I, 2001) |
| "Fluconazole was less effective against C." | 1.31 | The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. ( Abbas, J; Bodey, GP; Boktour, M; Girgawy, E; Hachem, RY; Hanna, HA; Kontoyiannis, DP; Mardani, M; Raad, II, 2002) |
| "parapsilosis in a cancer center within 10 years, with the aim to compare risk factors and the outcome with fungemias caused by C." | 1.30 | Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome. ( Grausová, S; Krcméry, V; Krupová, I; Mardiak, J; Roidová, A; Sálek, T; Spánik, S; Sufliarsky, J; Trupl, J, 1998) |
| "(NAC) in a single National Cancer Institution within 10 years were analysed for aetiology, risk factors and outcome." | 1.30 | Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution. ( Grey, E; Jurga, L; Krcmery, V; Kunova, A; Mardiak, J; Mateicka, F; Mrazova, M; Novotny, J; Sabo, A; Sevcikova, L; Sorkovska, D; Sufliarsky, J; Trupl, J; West, D, 1999) |
| "HSA levels in cancer patients were significantly decreased (p < 0." | 1.29 | Protein binding of itraconazole and fluconazole in patients with cancer. ( Arredondo, G; Calvo, R; Marcos, F; Martínez-Jordá, R; Suarez, E, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (3.39) | 18.7374 |
| 1990's | 43 (36.44) | 18.2507 |
| 2000's | 34 (28.81) | 29.6817 |
| 2010's | 26 (22.03) | 24.3611 |
| 2020's | 11 (9.32) | 2.80 |
| Authors | Studies |
|---|---|
| Lal, J | 1 |
| Gupta, SK | 1 |
| Thavaselvam, D | 1 |
| Agarwal, DD | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 1 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 1 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Shaikh, SKJ | 1 |
| Kamble, RR | 1 |
| Somagond, SM | 1 |
| Devarajegowda, HC | 1 |
| Dixit, SR | 1 |
| Joshi, SD | 1 |
| Zhao, Z | 1 |
| Li, X | 1 |
| Cui, Z | 1 |
| Tong, T | 1 |
| Zhang, Y | 2 |
| Yang, X | 1 |
| Keerthiga, R | 1 |
| Fu, C | 1 |
| Fu, A | 1 |
| Maheronnaghsh, M | 1 |
| Teimoori, A | 1 |
| Dehghan, P | 1 |
| Fatahinia, M | 1 |
| Tariq, B | 2 |
| Ou, YC | 2 |
| Stern, JC | 2 |
| Mundra, V | 2 |
| Wong Doo, N | 2 |
| Walker, P | 2 |
| Lewis, KL | 2 |
| Lin, C | 2 |
| Novotny, W | 2 |
| Sahasranaman, S | 2 |
| Opat, S | 2 |
| Monsen, RE | 1 |
| Kristoffersen, AK | 1 |
| Gay, CL | 1 |
| Herlofson, BB | 1 |
| Fjeld, KG | 1 |
| Hove, LH | 1 |
| Nordgarden, H | 1 |
| Tollisen, A | 1 |
| Lerdal, A | 1 |
| Enersen, M | 1 |
| Sharifi, M | 1 |
| Badiee, P | 2 |
| Abastabar, M | 2 |
| Morovati, H | 1 |
| Haghani, I | 1 |
| Noorbakhsh, M | 1 |
| Mohammadi, R | 1 |
| Velarde-Salcedo, R | 1 |
| Pérez-González, LF | 1 |
| Rodríguez-Báez, AS | 1 |
| Arriaga-García, FJ | 1 |
| Milán-Segovia, RDC | 1 |
| Romano-Moreno, S | 1 |
| Medellín-Garibay, SE | 1 |
| Tachibana, M | 1 |
| Matsuki, S | 1 |
| Maekawa, Y | 1 |
| Kuroda, K | 1 |
| Shimizu, T | 1 |
| Tsutsumi, J | 1 |
| Ishizuka, H | 1 |
| El-Mahallawy, HA | 1 |
| Abdelfattah, NE | 1 |
| Wassef, MA | 1 |
| Abdel-Hamid, RM | 1 |
| Souza E Silva, VC | 1 |
| Oliveira, VC | 1 |
| Sousa, ÁFL | 1 |
| Bim, FL | 1 |
| Macedo, AP | 1 |
| Andrade, D | 1 |
| Watanabe, E | 1 |
| De Rosa, FG | 1 |
| Busca, A | 1 |
| Capparella, MR | 1 |
| Yan, JL | 1 |
| Aram, JA | 1 |
| Amanati, A | 1 |
| Jafarian, H | 1 |
| Ghasemi, F | 1 |
| Nematolahi, S | 1 |
| Haghpanah, S | 1 |
| Hamzavi, SS | 1 |
| Lortholary, O | 1 |
| Renaudat, C | 1 |
| Sitbon, K | 1 |
| Desnos-Ollivier, M | 1 |
| Bretagne, S | 1 |
| Dromer, F | 1 |
| Le, A | 1 |
| Farmakiotis, D | 1 |
| Tarrand, JJ | 1 |
| Kontoyiannis, DP | 5 |
| Goel, G | 1 |
| Chandy, M | 1 |
| Bhattacharyya, A | 1 |
| Banerjee, S | 1 |
| Chatterjee, S | 1 |
| Mullick, S | 1 |
| Sinha, S | 1 |
| Sengupta, K | 1 |
| Dhar, K | 1 |
| Bhattacharya, S | 1 |
| Rudramurthy, S | 1 |
| Chakrabarti, A | 1 |
| Shokohi, T | 1 |
| Aslani, N | 2 |
| Ahangarkani, F | 1 |
| Meyabadi, MF | 1 |
| Hagen, F | 1 |
| Meis, JF | 2 |
| Boekhout, T | 2 |
| Kolecka, A | 1 |
| Badali, H | 2 |
| Janbabaei, G | 1 |
| Babaeian, M | 1 |
| Khodavaisy, S | 1 |
| Faessel, H | 1 |
| Nemunaitis, J | 1 |
| Bauer, TM | 1 |
| Lockhart, AC | 1 |
| Faller, DV | 1 |
| Sedarati, F | 1 |
| Zhou, X | 1 |
| Venkatakrishnan, K | 1 |
| Harvey, RD | 1 |
| Shigemura, K | 1 |
| Osawa, K | 1 |
| Jikimoto, T | 1 |
| Yoshida, H | 1 |
| Hayama, B | 1 |
| Ohji, G | 1 |
| Iwata, K | 1 |
| Fujisawa, M | 1 |
| Arakawa, S | 1 |
| Al Thaqafi, AH | 1 |
| Farahat, FM | 1 |
| Al Harbi, MI | 1 |
| Al Amri, AF | 1 |
| Perfect, JR | 1 |
| MOTTA, R | 1 |
| LUCCHESI, M | 1 |
| Jørgensen, KJ | 2 |
| Gøtzsche, PC | 5 |
| Dalbøge, CS | 1 |
| Johansen, HK | 7 |
| Cohen-Wolkowiez, M | 1 |
| Benjamin, DK | 1 |
| van der Elst, KC | 1 |
| Pereboom, M | 1 |
| van den Heuvel, ER | 1 |
| Kosterink, JG | 1 |
| Schölvinck, EH | 1 |
| Alffenaar, JW | 1 |
| Tang, HJ | 1 |
| Liu, WL | 1 |
| Lin, HL | 1 |
| Lai, CC | 1 |
| Döring, M | 1 |
| Eikemeier, M | 1 |
| Cabanillas Stanchi, KM | 1 |
| Hartmann, U | 1 |
| Ebinger, M | 1 |
| Schwarze, CP | 1 |
| Schulz, A | 1 |
| Handgretinger, R | 1 |
| Müller, I | 1 |
| Lagman, R | 1 |
| Davis, M | 1 |
| LeGrand, S | 1 |
| Walsh, D | 1 |
| Parala, A | 1 |
| Gamier, P | 1 |
| Cothren, B | 1 |
| Cheema, B | 1 |
| Gopal, S | 1 |
| Rybicki, L | 1 |
| Fitterer, C | 1 |
| Berg, Z | 1 |
| Halfdanarson, TR | 1 |
| Vikram, HR | 1 |
| Kusne, S | 1 |
| Orenstein, R | 1 |
| Seville, MT | 1 |
| Blair, JE | 1 |
| Blyth, CC | 1 |
| Chen, SC | 2 |
| Slavin, MA | 2 |
| Serena, C | 1 |
| Nguyen, Q | 2 |
| Marriott, D | 2 |
| Ellis, D | 1 |
| Meyer, W | 1 |
| Sorrell, TC | 2 |
| Lemachatti, J | 1 |
| Levêque, D | 1 |
| Beretz, L | 1 |
| Bergerat, JP | 1 |
| Thursky, KA | 1 |
| Ellis, DH | 1 |
| Morrissey, CO | 1 |
| Sobrevilla Calvo, P | 1 |
| Sun, J | 1 |
| Qi, C | 1 |
| Lafleur, MD | 1 |
| Qi, QG | 1 |
| Dranitsaris, G | 1 |
| Khoury, H | 1 |
| Mitrokhin, SD | 1 |
| Sokolov, AA | 1 |
| Gammelsrud, KW | 1 |
| Lindstad, BL | 1 |
| Gaustad, P | 1 |
| Ingebretsen, A | 1 |
| Høiby, EA | 1 |
| Brandtzaeg, P | 1 |
| Sandven, P | 2 |
| Ethier, MC | 1 |
| Science, M | 1 |
| Beyene, J | 1 |
| Briel, M | 1 |
| Lehrnbecher, T | 1 |
| Sung, L | 1 |
| Garbino, J | 1 |
| Kolarova, L | 1 |
| Rohner, P | 1 |
| Lew, D | 1 |
| Pichna, P | 3 |
| Pittet, D | 1 |
| Borisy, AA | 1 |
| Elliott, PJ | 1 |
| Hurst, NW | 1 |
| Lee, MS | 1 |
| Lehar, J | 1 |
| Price, ER | 1 |
| Serbedzija, G | 1 |
| Zimmermann, GR | 1 |
| Foley, MA | 1 |
| Stockwell, BR | 1 |
| Keith, CT | 1 |
| GUIMARAES, JP | 1 |
| MOTTA, MC | 1 |
| SOROF, S | 1 |
| YOUNG, EM | 1 |
| MCCUE, MM | 1 |
| FETTERMAN, PL | 1 |
| RAKOV, AI | 1 |
| Bagg, J | 2 |
| Sweeney, MP | 2 |
| Lewis, MA | 1 |
| Jackson, MS | 2 |
| Coleman, D | 1 |
| Al, MA | 1 |
| Baxter, W | 1 |
| McEndrick, S | 1 |
| McHugh, S | 1 |
| Antoniadou, A | 1 |
| Torres, HA | 2 |
| Lewis, RE | 1 |
| Thornby, J | 1 |
| Bodey, GP | 4 |
| Tarrand, JP | 1 |
| Han, XY | 1 |
| Rolston, KV | 2 |
| Safdar, A | 1 |
| Raad, II | 2 |
| Oude Lashof, AM | 1 |
| De Bock, R | 1 |
| Herbrecht, R | 1 |
| de Pauw, BE | 1 |
| Krcmery, V | 14 |
| Aoun, M | 1 |
| Akova, M | 2 |
| Cohen, J | 1 |
| Siffnerová, H | 1 |
| Egyed, M | 1 |
| Ellis, M | 1 |
| Marinus, A | 1 |
| Sylvester, R | 1 |
| Kullberg, BJ | 1 |
| Ozçelik, B | 1 |
| Citak, S | 1 |
| Cesur, S | 1 |
| Abbasoğlu, U | 1 |
| Içli, F | 1 |
| Hiemenz, J | 1 |
| Cagnoni, P | 1 |
| Simpson, D | 1 |
| Devine, S | 1 |
| Chao, N | 1 |
| Keirns, J | 1 |
| Lau, W | 1 |
| Facklam, D | 1 |
| Buell, D | 1 |
| Laupland, KB | 1 |
| Gregson, DB | 1 |
| Church, DL | 1 |
| Ross, T | 1 |
| Elsayed, S | 1 |
| Torfoss, D | 1 |
| Davies, AN | 1 |
| Brailsford, S | 1 |
| Kiertiburanakul, S | 1 |
| Wirojtananugoon, S | 1 |
| Pracharktam, R | 1 |
| Sungkanuparph, S | 1 |
| Cheng, YR | 1 |
| Lin, LC | 1 |
| Young, TG | 1 |
| Liu, CE | 1 |
| Chen, CH | 1 |
| Tsay, RW | 1 |
| Nakamura, T | 1 |
| Takahashi, H | 1 |
| Giusiano, G | 1 |
| Mangiaterra, M | 1 |
| Garcia Saito, V | 1 |
| Rojas, F | 1 |
| Gómez, V | 1 |
| Díaz, MC | 1 |
| Lunardi, LW | 1 |
| Aquino, VR | 1 |
| Zimerman, RA | 1 |
| Goldani, LZ | 1 |
| Yu, DT | 1 |
| Seger, DL | 1 |
| Peterson, JF | 1 |
| Kumar, RN | 1 |
| Bates, DW | 1 |
| Depont, F | 1 |
| Vargas, F | 1 |
| Dutronc, H | 1 |
| Giauque, E | 1 |
| Ragnaud, JM | 1 |
| Galpérine, T | 1 |
| Abouelfath, A | 1 |
| Valentino, R | 1 |
| Dupon, M | 1 |
| Hébert, G | 1 |
| Moore, N | 1 |
| Gonzalez, AV | 1 |
| Ullmann, AJ | 1 |
| Almyroudis, NG | 1 |
| Segal, BH | 1 |
| Kersun, LS | 1 |
| Reilly, AF | 1 |
| Ingram, ME | 1 |
| Nicholaou, MJ | 1 |
| McGowan, KL | 1 |
| Arning, M | 1 |
| Aul, C | 1 |
| Yamaç, K | 1 |
| Senol, E | 1 |
| Haznedar, R | 1 |
| Meunier, F | 1 |
| Anaissie, EJ | 1 |
| Huls, C | 1 |
| Vartivarian, SE | 1 |
| Karl, C | 1 |
| Prince, RA | 1 |
| Bosso, J | 1 |
| Schuler, U | 1 |
| Mölle, M | 1 |
| Ehninger, G | 1 |
| Flynn, PM | 1 |
| Cunningham, CK | 1 |
| Kerkering, T | 1 |
| San Jorge, AR | 1 |
| Peters, VB | 1 |
| Pitel, PA | 1 |
| Harris, J | 1 |
| Gilbert, G | 1 |
| Castagnaro, L | 1 |
| Robinson, P | 1 |
| McCann, J | 1 |
| Ninane, J | 1 |
| Fukuda, M | 1 |
| Hirashima, K | 1 |
| Kurane, R | 1 |
| Abe, T | 1 |
| Sampi, K | 1 |
| Tominaga, K | 1 |
| Tsuji, M | 1 |
| Takagi, S | 1 |
| Naito, T | 1 |
| Wingard, JR | 2 |
| Akalin, HE | 1 |
| Uzun, O | 1 |
| Hayran, M | 1 |
| Tekuzman, G | 1 |
| Kansu, E | 1 |
| Aslan, S | 1 |
| Telatar, H | 1 |
| Fasano, C | 1 |
| O'Keeffe, J | 1 |
| Gibbs, D | 1 |
| Martino, P | 1 |
| Girmenia, C | 1 |
| Broun, ER | 1 |
| Wheat, JL | 1 |
| Kneebone, PH | 1 |
| Sundblad, K | 1 |
| Hromas, RA | 1 |
| Tricot, G | 1 |
| Goa, KL | 1 |
| Barradell, LB | 1 |
| Arredondo, G | 1 |
| Calvo, R | 1 |
| Marcos, F | 1 |
| Martínez-Jordá, R | 1 |
| Suarez, E | 1 |
| Powles, RL | 1 |
| Mehta, J | 1 |
| Studena, V | 1 |
| Sycova, Z | 1 |
| Helpianska, L | 1 |
| Sorkovska, D | 2 |
| Lacka, J | 2 |
| Hlavacova, E | 1 |
| Oravcova, E | 3 |
| Studena, M | 1 |
| D'Antonio, D | 1 |
| Mazzoni, A | 1 |
| Iacone, A | 1 |
| Violante, B | 1 |
| Capuani, MA | 1 |
| Schioppa, F | 1 |
| Romano, F | 1 |
| Viscoli, C | 2 |
| Castagnola, E | 2 |
| Van Lint, MT | 1 |
| Moroni, C | 1 |
| Garaventa, A | 1 |
| Rossi, MR | 1 |
| Fanci, R | 1 |
| Menichetti, F | 1 |
| Caselli, D | 1 |
| Giacchino, M | 1 |
| Congiu, M | 1 |
| Espejo Martínez, J | 1 |
| Alvarez Medina, MP | 1 |
| Sánchez Morales, S | 1 |
| Machetti, M | 1 |
| Trupl, J | 7 |
| Kunová, A | 6 |
| Kukucková, E | 2 |
| Grausova, S | 4 |
| Grey, E | 3 |
| Spanik, S | 6 |
| Demitrovicová, A | 2 |
| Kralóvicová, K | 2 |
| Krupova, I | 5 |
| Svec, J | 1 |
| Koren, P | 1 |
| Groll, AH | 2 |
| Just-Nuebling, G | 1 |
| Kurz, M | 1 |
| Mueller, C | 1 |
| Nowak-Goettl, U | 1 |
| Schwabe, D | 1 |
| Shah, PM | 1 |
| Kornhuber, B | 1 |
| Boschman, CR | 1 |
| Bodnar, UR | 1 |
| Tornatore, MA | 1 |
| Obias, AA | 1 |
| Noskin, GA | 1 |
| Englund, K | 1 |
| Postelnick, MA | 1 |
| Suriano, T | 1 |
| Peterson, LR | 1 |
| Mrazova-Studena, M | 1 |
| Stopkova-Grey, K | 1 |
| Kaiserova, E | 1 |
| Foltinova, A | 1 |
| Kovacicova, G | 2 |
| Kiskova, M | 1 |
| Krchnakova, A | 1 |
| West, D | 2 |
| Malik, IA | 1 |
| Moid, I | 1 |
| Aziz, Z | 1 |
| Khan, S | 1 |
| Suleman, M | 1 |
| Krupova, Y | 3 |
| Novotny, J | 2 |
| Sabo, A | 3 |
| Mateicka, F | 4 |
| Roidová, A | 2 |
| Sálek, T | 1 |
| Sufliarsky, J | 4 |
| Mardiak, J | 3 |
| Hanzen, J | 2 |
| Pichnova, E | 1 |
| Mrazova, M | 1 |
| Jurga, L | 1 |
| Sevcikova, L | 1 |
| Gotzsche, PC | 2 |
| Offidani, M | 1 |
| Corvatta, L | 1 |
| Olivieri, A | 1 |
| Rupoli, S | 1 |
| Frayfer, J | 1 |
| Mele, A | 1 |
| Manso, E | 1 |
| Montanari, M | 1 |
| Centurioni, R | 1 |
| Leoni, P | 1 |
| Fuksiewicz, A | 1 |
| Połowniak-Pracka, H | 1 |
| Ochman, E | 1 |
| Podsiadło, B | 1 |
| Kanda, Y | 1 |
| Yamamoto, R | 1 |
| Chizuka, A | 1 |
| Hamaki, T | 1 |
| Suguro, M | 1 |
| Arai, C | 1 |
| Matsuyama, T | 1 |
| Takezako, N | 1 |
| Miwa, A | 1 |
| Kern, W | 1 |
| Kami, M | 1 |
| Akiyama, H | 1 |
| Hirai, H | 1 |
| Togawa, A | 1 |
| Winston, DJ | 1 |
| Hathorn, JW | 1 |
| Schuster, MG | 1 |
| Schiller, GJ | 1 |
| Territo, MC | 1 |
| Minari, A | 1 |
| Hachem, R | 1 |
| Raad, I | 1 |
| Mistrik, M | 1 |
| Bojtarova, E | 1 |
| Sejnova, D | 1 |
| Ilavska, I | 1 |
| Ritter, J | 1 |
| Müller, FM | 1 |
| Lovaszova, M | 1 |
| Liskova, A | 1 |
| Milosovic, P | 1 |
| Lamosova, M | 1 |
| Macekova, L | 1 |
| Szovenyiova, Z | 1 |
| Purgelova, A | 1 |
| Obertik, T | 1 |
| Bille, J | 1 |
| Mardani, M | 1 |
| Hanna, HA | 1 |
| Boktour, M | 1 |
| Abbas, J | 1 |
| Girgawy, E | 1 |
| Hachem, RY | 1 |
| Nucci, M | 1 |
| Colombo, AL | 1 |
| Hughes, WT | 1 |
| Koza, I | 2 |
| Hornikova, M | 2 |
| Fuchsberger, P | 1 |
| Blahova, M | 1 |
| Savko, V | 1 |
| Migom, C | 1 |
| Samonis, G | 1 |
| Rolston, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Drug-Drug Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Patients With B-Cell Malignancies[NCT04551963] | Phase 1 | 26 participants (Actual) | Interventional | 2020-11-15 | Completed | ||
| Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole Or Fluconazole Therapy, For Treatment Of Documented Candidemia/Invasive Candidiasis In Intensive Care Unit Patient Populations[NCT00689338] | Phase 3 | 216 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Patients With Candida Deep Tissue Infection[NCT00805740] | Phase 3 | 41 participants (Actual) | Interventional | 2009-04-30 | Terminated (stopped due to The study was terminated prematurely on May 18, 2012 due to slow enrollment. The study was not terminated due to any safety issues or concerns.) | ||
| Efficacy And Safety Of Eraxis/Ecalta (Anidulafungin) Compared To Cancidas (Caspofungin) In Neutropenic Patients With Invasive Candida Infection[NCT00806351] | Phase 3 | 21 participants (Actual) | Interventional | 2009-08-31 | Terminated (stopped due to The study was prematurely terminated on May 18, 2012 due to slow enrollment. The study was not terminate due to any safety issues or concerns.) | ||
| Open-Label, Non-Comparative, Study Of Intravenous Anidulafungin, Followed Optionally By Oral Voriconazole, For Treatment Of Documented Candidemia/Invasive Candidiasis In Hospitalized Patients[NCT00548262] | Phase 4 | 54 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| Phase IV Open Label Non Comparative Trial Of IV Anidulafungin Followed By Oral Azole Therapy For The Treatment Of Candidemia And Invasive Candidiasis[NCT00496197] | Phase 4 | 282 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| A Phase IIIB Pilot Study Of Efficacy And Safety Of Anidulafungin In The Treatment Of Candidemia In Asian Patients[NCT00537329] | Phase 3 | 43 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Invasive Fungal Infections in Patients Following Stem Cell Transplant[NCT04619147] | 300 participants (Anticipated) | Observational | 2021-01-31 | Not yet recruiting | |||
| Pharmacokinetics of a Fluconazole Loading Dose in Infants and Toddlers[NCT00797420] | Phase 1 | 13 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| ANTIVORIFUNGOL:Strategy of Antifungal Use in Oncohematological Neutropenic Patients. Use of Voriconazole as Early Treatment.[NCT00386802] | Phase 4 | 115 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis[NCT00723073] | 323 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | Hours (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg BID + 400 mg fluconazole QD | Zanubrutinib 80 mg BID + 180 mg diltiazem QD | |
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 2.15 | 2.10 | 2.14 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | h*ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg BID + 400 mg fluconazole QD | Zanubrutinib 80 mg BID + 180 mg diltiazem QD | |
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 2035.32 | 1911.93 | 1653.07 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | h*ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg BID + 400 mg fluconazole QD | Zanubrutinib 80 mg BID + 180 mg diltiazem QD | |
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 1899.32 | 921.63 | 797.87 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg BID + 400 mg fluconazole QD | Zanubrutinib 80 mg BID + 180 mg diltiazem QD | |
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 520.78 | 235.72 | 211.06 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | Hours (Median) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg BID + 400 mg fluconazole QD | Zanubrutinib 80 mg BID + 180 mg diltiazem QD | |
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 2.03 | 2.93 | 2.05 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | Hours (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg QD + 200 mg voriconazole BID | Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 1.79 | 2.38 | 2.08 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | h*ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg QD + 200 mg voriconazole BID | Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 1578.12 | 1376.02 | 766.71 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | h*ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg QD + 200 mg voriconazole BID | Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 1550.40 | 1254.29 | 763.00 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | ng/mL (Geometric Mean) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg QD + 200 mg voriconazole BID | Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 428.88 | 353.11 | 215.15 |
(NCT04551963)
Timeframe: Predose, 0.5, 1, 2, 3, 4, 6, 8 and 10 hours on Cycle 1 Day 3, Day 10, and Day 28 (30-day cycle)
| Intervention | Hours (Median) | ||
|---|---|---|---|
| Zanubrutinib 320 mg QD | Zanubrutinib 80 mg QD + 200 mg voriconazole BID | Zanubrutinib 80 mg QD + 250 mg clarithromycin BID | |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 3.00 | 2.05 | 2.08 |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinical laboratory tests (NCT04551963)
Timeframe: From the date of first study drug administration to 30 days after last dose (up to approximately 15 months)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| At least one TEAE | At least one SAE | |
| Arm A: Zanubrutinib With or Without Moderate CYP3A | 12 | 3 |
| Arm B: Zanubrutinib With or Without Strong CYP3A | 12 | 1 |
Percentage of participants known or assumed to be alive on Day 90. (NCT00689338)
Timeframe: Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 54.1 |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success). (NCT00689338)
Timeframe: 6 weeks after End of Treatment (Day 14 + 42 up to Day 56 + 42)
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 50.5 |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success). (NCT00689338)
Timeframe: 2 weeks after End of Treatment (Day 14 + 14 up to Day 56 + 14)
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 60.2 |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success). (NCT00689338)
Timeframe: EOIVT (Day 10 up to Day 42)
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 70.7 |
Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success). (NCT00689338)
Timeframe: End of Treatment (Day 14 to Day 56)
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 69.5 |
Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication. (NCT00689338)
Timeframe: Day 1 up to Day 42
| Intervention | days (Mean) |
|---|---|
| Anidulafungin | 3.7 |
Time from start of study medication to successful ICU discharge (by end of treatment [EOT]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT. (NCT00689338)
Timeframe: Day 1 up to Day 56
| Intervention | days (Mean) |
|---|---|
| Anidulafungin | 16.2 |
A participant had a successful clinical response if there was clinical response of cure or improvement. Clinical response of cure: resolution of signs and symptoms attributed to Candida infection; no additional systemic or oral antifungal treatment required to complete the course of therapy. Clinical response of improvement: significant, but incomplete resolution of signs and symptoms of Candida infection; no additional systemic or oral antifungal treatment required. (NCT00805740)
Timeframe: Day 10
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 70.8 |
| Caspofungin | 76.9 |
Participants had successful global response if there was clinical response of cure/improvement,microbiological eradication/presumed eradication.Clinical cure:resolution of signs/symptoms (s/s) of Candida infection;no additional systemic/oral antifungal treatment needed.Clinical improvement:significant,but incomplete resolution of s/s of Candida infection;no additional systemic/oral antifungal treatment needed.Microbiological eradication/presumed eradication:baseline pathogen not isolated from original site culture,or culture data not available for participant with successful clinical outcome. (NCT00805740)
Timeframe: End of Treatment (Day 14 to Day 42)
| Intervention | percentage of participants (Number) |
|---|---|
| Anidulafungin | 83.3 |
| Caspofungin | 61.5 |
Time to death (days) was assessed as date of death minus first treatment date plus 1. (NCT00805740)
Timeframe: Baseline up to 6-week follow-up (6 weeks after EOT)
| Intervention | days (Median) |
|---|---|
| Anidulafungin | 23.0 |
| Caspofungin | 11.5 |
Negative blood culture referred to absence of Candida sp. in the blood sample of participants who had a positive blood culture at baseline. Time to negative blood culture (days) was calculated as date of first negative blood culture minus first treatment date plus 1. (NCT00805740)
Timeframe: Baseline up to 6-week follow-up (6 weeks after EOT)
| Intervention | days (Median) |
|---|---|
| Anidulafungin | 2.0 |
| Caspofungin | 3.5 |
All-cause mortality during study therapy and at follow-up visits reported as unique death at EOT, 2 week follow-up and 6 week follow-up. (NCT00805740)
Timeframe: Baseline to EOT (Day 14 to 42), After EOT to 2-week follow-up (2 weeks after EOT), After 2-week follow-up to 6-week follow-up (6 weeks after EOT)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| Baseline to EOT | After EOT to 2-week follow-up | After 2-week follow-up to 6-week follow-up | |
| Anidulafungin | 3.8 | 15.4 | 7.7 |
| Caspofungin | 15.4 | 15.4 | 0.0 |
Participants had successful global response if there was clinical response of cure/improvement,microbiological eradication/presumed eradication.Clinical cure:resolution of signs/symptoms (s/s) of Candida infection;no additional systemic/oral antifungal treatment needed.Clinical improvement:significant,but incomplete resolution of s/s of Candida infection;no additional systemic/oral antifungal treatment needed.Microbiological eradication/presumed eradication:baseline pathogen not isolated from original site culture,or culture data not available for participant with successful clinical outcome. (NCT00805740)
Timeframe: 2-week follow-up (2 weeks after end of treatment [EOT]), 6-week follow-up (6 weeks after EOT)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-week follow-up | 6-week follow-up | |
| Anidulafungin | 76.2 | 66.7 |
| Caspofungin | 54.5 | 54.5 |
New Infection: participant presenting with clinical failure with the emergence of new Candida sp. at the original site of infection or at a distant site of infection. Clinical failure: no significant improvement in signs and symptoms, or death due to Candida infection. Participants must have had received at least 3 doses of study drug to be classified as a failure. (NCT00805740)
Timeframe: 2-week follow-up (2 weeks after EOT), 6-week follow-up (6 weeks after EOT)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-week follow-up | 6-week follow-up | |
| Anidulafungin | 0 | 0 |
| Caspofungin | 0 | 0 |
Relapse was defined as any baseline Candida sp. isolated following eradication (documented or presumed) or culture data not available for participants with a clinical response of failure after a previous response of success. Prophylactic treatment with oral antifungal agents was not sufficient to document a relapse. (NCT00805740)
Timeframe: 2-week follow-up (2 weeks after EOT), 6-week follow-up (6 weeks after EOT)
| Intervention | percentage of participants (Number) | |
|---|---|---|
| 2-week follow-up | 6-week follow-up | |
| Anidulafungin | 0 | 0 |
| Caspofungin | 0 | 0 |
A participant had a successful response if there was clinical response of cure and microbiological success (eradication or presumed eradication). Clinical response of cure: resolution of signs and symptoms attributed to Candida infection; no additional systemic or oral antifungal treatment required to complete the course of therapy. Microbiological eradication or presumed eradication: baseline pathogen not isolated from original site culture, or culture data not available for a participant with successful clinical outcome. (NCT00805740)
Timeframe: EOT (Day 14 to 42), 2-week follow-up (2 weeks after EOT), 6-week follow-up (6 weeks after EOT)
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| EOT (n=21,8) | 2-week follow-up (n=16,6) | 6-week follow-up (n=15,6) | |
| Anidulafungin | 81.0 | 87.5 | 93.3 |
| Caspofungin | 62.5 | 100.0 | 100.0 |
Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]). (NCT00806351)
Timeframe: 2 weeks post treatment
| Intervention | participants (Number) |
|---|---|
| Anidulafungin | 4 |
| Caspofungin | 1 |
Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]). (NCT00806351)
Timeframe: 6 weeks post treatment
| Intervention | participants (Number) |
|---|---|
| Anidulafungin | 6 |
| Caspofungin | 1 |
Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]). (NCT00806351)
Timeframe: Day 10 up to Day 42
| Intervention | participants (Number) |
|---|---|
| Anidulafungin | 7 |
| Caspofungin | 2 |
Participant counts of clinical cure (no s/s of Candida) and microbiological success (eradication [f/u culture negative] or presumed eradication [f/u culture not available and a clinical response of cure]). (NCT00806351)
Timeframe: Day 14 up to Day 56
| Intervention | participants (Number) |
|---|---|
| Anidulafungin | 6 |
| Caspofungin | 3 |
Time to death defined as: date of death minus first treatment date plus 1. (NCT00806351)
Timeframe: Day 1 up to Day 98
| Intervention | days (Median) |
|---|---|
| Anidulafungin | 34.0 |
| Caspofungin | 15.5 |
A participant had a negative blood culture, if having determined the day of the first negative blood culture, the subsequent blood culture was also negative, or if positive, the interval between the cultures was at least 2 days. For participants whose blood culture went from positive to negative, the time to negative blood culture defined as: date of first negative blood culture minus first treatment date plus 1. (NCT00806351)
Timeframe: Baseline up to Day 56
| Intervention | days (Median) |
|---|---|
| Anidulafungin | 2.0 |
All-cause mortality during study therapy and at follow-up visits reported as unique deaths at EOIVT, end of oral treatment (EOT-oral), 2 Week Follow-Up and 6 Week Follow-Up (NCT00806351)
Timeframe: Baseline up to 6 weeks post treatment
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| at EOIVT | at EOT - oral | at 2 Week Follow-Up Visit | at 6 Week Follow-Up Visit | |
| Anidulafungin | 1 | 1 | 1 | 2 |
| Caspofungin | 1 | 0 | 3 | 0 |
Participant counts of clinical response categorized as success, failure, or indeterminate. Success: no s/s of Candida (cure) or significant but incomplete resolution of s/s of Candida; no additional systemic or oral antifungal treatment required (improvement). Failure: worsening of s/s of the Candida infection. Indeterminate: evaluation could not be made due to withdrawal from study prior to assessment of cure or failure. Participants who received fewer than 3 doses of study medication were assigned a clinical efficacy response of indeterminate. (NCT00806351)
Timeframe: Day 10
| Intervention | participants (Number) | ||
|---|---|---|---|
| Success | Failure | Indeterminate | |
| Anidulafungin | 7 | 0 | 2 |
| Caspofungin | 3 | 0 | 0 |
Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (≥3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse). (NCT00806351)
Timeframe: 2 weeks post treatment
| Intervention | participants (Number) | ||
|---|---|---|---|
| Success | Failure | Indeterminate | |
| Anidulafungin | 6 | 3 | 0 |
| Caspofungin | 1 | 0 | 0 |
Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (≥3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse). (NCT00806351)
Timeframe: 6 weeks post treatment
| Intervention | participants (Number) | ||
|---|---|---|---|
| Success | Failure | Indeterminate | |
| Anidulafungin | 5 | 4 | 0 |
| Caspofungin | 1 | 0 | 0 |
Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no signs, symptoms [s/s] of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (follow-up [f/u] culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (greater than or equal to [≥3] doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent(positive culture any Candida species [sp]), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse). (NCT00806351)
Timeframe: Day 10 up to Day 42
| Intervention | participants (Number) | ||
|---|---|---|---|
| Success | Failure | Indeterminate | |
| Anidulafungin | 8 | 3 | 0 |
| Caspofungin | 3 | 0 | 0 |
Participant counts of global response of success, failure, or indeterminate. Success: clinical response of cure (no s/s of Candida) or improvement (significant, incomplete resolution of s/s) and microbiological response of eradication (f/u culture negative) or presumed eradication (f/u culture not available and clinical success). Failure: clinical response of failure (≥3 doses study medication and no significant improvement of s/s or death due to Candida) and/or unsuccessful microbiological response of persistent (positive culture any Candida sp), new infection or relapse at f/u. Indeterminate: clinical and/or microbiological response of indeterminate (evaluation could not be made due to withdrawal from study prior to assessment of cure or failure) and there was neither clinical response of failure nor unsuccessful microbiological response (persistence or new infection or relapse). (NCT00806351)
Timeframe: Day 14 up to Day 56
| Intervention | participants (Number) | ||
|---|---|---|---|
| Success | Failure | Indeterminate | |
| Anidulafungin | 8 | 3 | 0 |
| Caspofungin | 3 | 0 | 0 |
Participant counts of microbiologic response of new infection defined as clinical failure with emergence of new Candida sp not identified at baseline at the original site of infection or at a distant site of infection. Clinical failure defined as ≥3 doses study medication and no significant improvement of s/s or death due to Candida. (NCT00806351)
Timeframe: 2 and 6 weeks post treatment
| Intervention | participants (Number) | |
|---|---|---|
| 2 weeks post treatment | 6 weeks post treatment | |
| Anidulafungin | 0 | 0 |
| Caspofungin | 0 | 0 |
Participant counts of microbiologic response of recurrence defined as any baseline Candida sp isolated following eradication, or culture data were not available for participants with a clinical response of failure after a previous response of success. Clinical failure defined as ≥3 doses study medication and no significant improvement of s/s or death due to Candida. Clinical success is resolution of s/s and no additional antifungal treatment needed. (NCT00806351)
Timeframe: 2 and 6 weeks post treatment
| Intervention | participants (Number) | |
|---|---|---|
| 2 Weeks post treatment | 6 Weeks post treatment | |
| Anidulafungin | 0 | 0 |
| Caspofungin | 0 | 0 |
Defined as time in days from first intravenous administration of Anidulafungin to the date of earliest recorded documentation of switch to oral Voriconazole treatment. Participants received at least 5 days (and a maximum of 42 days) of IV Anidulafungin; after this, they may continue treatment with oral Voriconazole for at least 14 days from the day of last positive culture up to a maximum of 42 days. (NCT00548262)
Timeframe: Baseline to Day 42
| Intervention | days (Median) |
|---|---|
| Anidulafungin-Voriconazole | 10.0 |
Defined as the number of days from date of first drug administration to date of first ICU discharge. Week 6 Follow-up visit conducted by phone. (NCT00548262)
Timeframe: Baseline up to Week 6 Follow-up
| Intervention | Days (Median) |
|---|---|
| Anidulafungin-Voriconazole | 16.0 |
Chemistry laboratory test data measured as international units per (IU/L). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | IU/L (Median) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline median: aspartate aminotransferase (n=18) | Change from baseline: aspartate aminotransferase | Baseline median: alanine aminotransferase (n=16) | Change from baseline: alanine aminotransferase | Baseline median: lactate dehydrogenase (n=13) | Change from baseline: lactate dehydrogenase | Baseline median: alkaline phosphatase (n=17) | Change from baseline: alkaline phosphatase | |
| Anidulafungin-Voriconazole | 43 | -18 | 45 | -5 | 536 | -160 | 114 | 26 |
Chemistry laboratory test data measured as milligrams per deciliter (mg/dL). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | mg/dL (Median) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline median: total bilirubin (n=19) | Change from baseline: total bilirubin | Baseline median: direct bilirubin (n=19) | Change from baseline: direct bilirubin | Baseline median: indirect bilirubin (n=17) | Change from baseline: indirect bilirubin | Baseline median: blood urea nitrogen (n=25) | Change from baseline: blood urea nitrogen | Baseline median: creatinine (n=27) | Change from baseline: creatinine | Baseline median: glucose (n=24) | Change from baseline: glucose | |
| Anidulafungin-Voriconazole | 0.6 | -0.2 | 0.2 | -0.1 | 0.3 | 0.0 | 37.4 | -4.8 | 0.8 | 0.0 | 99 | -6 |
Respiration rate measured as respirations per minute (resp/min). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | resp/min (Median) | |
|---|---|---|
| Baseline median: respiration rate | Change from baseline: respiration rate | |
| Anidulafungin-Voriconazole | 20.0 | -0.50 |
Supine systolic and diastolic blood pressure BP) measured as millimeters of mercury (mmHg). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | mmHg (Median) | |||
|---|---|---|---|---|
| Baseline median: supine systolic BP | Change from baseline: supine systolic BP | Baseline median: supine diastolic BP | Change from baseline: supine diastolic BP | |
| Anidulafungin-Voriconazole | 120.0 | 0.00 | 66.0 | 0.00 |
Supine heart rate measured as beats per minute (bpm). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | bpm (Median) | |
|---|---|---|
| Baseline median: supine heart rate | Change from baseline: supine heart rate | |
| Anidulafungin-Voriconazole | 97.5 | 3.00 |
Temperature measured as degrees of Celsius (C). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | Degrees of Celsius (Median) | |
|---|---|---|
| Baseline median: temperature | Change from baseline: temperature | |
| Anidulafungin-Voriconazole | 37.5 | -0.30 |
Weight measured as kilograms (kg). (NCT00548262)
Timeframe: Baseline to Week 2 Follow-up
| Intervention | kg (Median) | |
|---|---|---|
| Baseline median: weight | Change from baseline: weight | |
| Anidulafungin-Voriconazole | 65.0 | -0.70 |
Clinical Success (cure=resolution of Candida signs and symptoms [s/s] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure). (NCT00548262)
Timeframe: End of Intravenous Treatment (EIVT) (up to Day 42), Week 2 Follow-up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| EIVT Success | EIVT Failure | Week 2 Follow-up Success | Week 2 Follow-up Failure | |
| Anidulafungin-Voriconazole | 26 | 18 | 21 | 23 |
Clinical Success (cure=resolution of Candida signs and symptoms [s/s] or improvement=significant but incomplete resolution of s/s) or Failure (at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological Success (eradication=negative culture for baseline Candida species (spp) or presumed eradication=follow-up (f/u) culture not available (n/a) and clinical outcome defined as success) or Failure (persistence=positive culture for at least 1 baseline Candida spp or presumed persistence=f/u culture n/a and clinical outcome defined as failure). (NCT00548262)
Timeframe: End of Treatment (EOT) (up to Day 42)
| Intervention | participants (Number) | |
|---|---|---|
| Success | Failure | |
| Anidulafungin-Voriconazole | 26 | 18 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response assessed as APACHE II score <20 (less affected) or ≥20 (more severe). APACHE II assesses severity of illness in acutely ill participants; measurements computed for physiologic variables were transformed to integer score ranging 0 (normal) to 71 (more severe). Higher scores indicate more severe disease and higher risk of death. (NCT00548262)
Timeframe: EIVT (up to Day 42), EOT (up to Day 42), Week 2 Follow-up
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APACHE <20 (EIVT): Success | APACHE <20 (EIVT): Failure | APACHE ≥20 (EIVT): Success | APACHE ≥20 (EIVT): Failure | APACHE <20 (EOT): Success | APACHE <20 (EOT): Failure | APACHE ≥20 (EOT): Success | APACHE ≥20 (EOT): Failure | APACHE <20 (Week 2 F/U): Success | APACHE <20 (Week 2 F/U): Failure | APACHE ≥20 (Week 2 F/U): Success | APACHE ≥20 (Week 2 F/U): Failure | |
| Anidulafungin-Voriconazole | 24 | 11 | 2 | 7 | 25 | 10 | 1 | 8 | 20 | 15 | 1 | 8 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EIVT was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly. (NCT00548262)
Timeframe: EIVT (up to Day 42)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICU stay ≥ 4 days (Yes): Success | ICU stay ≥ 4 days (Yes): Failure | ICU stay ≥ 4 days (No): Success | ICU stay ≥ 4 days (No): Failure | Mechanical ventilation (Yes): Success | Mechanical ventilation (Yes): Failure | Mechanical ventilation (No): Success | Mechanical ventilation (No): Failure | Antibiotics (Yes): Success | Antibiotics (Yes): Failure | Antibiotics (No): Success | Antibiotics (No): Failure | CV Catheter (Yes): Success | CV Catheter (Yes): Failure | CV Catheter (No): Success | CV Catheter (No): Failure | TPN (Yes): Success | TPN (Yes): Failure | TPN (No): Success | TPN (No): Failure | Dialysis (Yes): Success | Dialysis (Yes): Failure | Dialysis (No): Success | Dialysis (No): Failure | Abdominal surgery (Yes): Success | Abdominal surgery (Yes): Failure | Abdominal surgery (No): Success | Abdominal surgery (No): Failure | Solid organ transplant (No): Success | Solid organ transplant (No): Failure | Renal insufficiency (Yes): Success | Renal insufficiency (Yes): Failure | Renal insufficiency (No): Success | Renal insufficiency (No): Failure | Chemotherapy (Yes): Success | Chemotherapy (Yes): Failure | Chemotherapy (No): Success | Chemotherapy (No): Failure | Pancreatitis (Yes): Success | Pancreatitis (Yes): Failure | Pancreatitis (No): Success | Pancreatitis (No): Failure | Systemic steroids/immunos (Yes): Success | Systemic steroids/immunos (Yes): Failure | Systemic steroids/immunos (No): Success | Systemic steroids/immunos (No): Failure | Neutropenic: Success | Neutropenic: Failure | Non-neutropenic: Success | Non-neutropenic: Failure | |
| Anidulafungin-Voriconazole | 18 | 14 | 8 | 4 | 18 | 15 | 8 | 3 | 22 | 17 | 4 | 1 | 21 | 17 | 5 | 1 | 6 | 7 | 20 | 11 | 3 | 4 | 23 | 14 | 12 | 7 | 14 | 11 | 26 | 18 | 3 | 4 | 23 | 14 | 1 | 0 | 25 | 18 | 2 | 3 | 24 | 15 | 7 | 5 | 19 | 13 | 2 | 1 | 18 | 11 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at Week 2 F/U was assessed for participants categorized with baseline risk factors for Candidemia and Invasive Candidiasis: ICU stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly. (NCT00548262)
Timeframe: Baseline, Week 2 Follow-up (F/U)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICU stay ≥ 4 days (Yes): Success | ICU stay ≥ 4 days (Yes): Failure | ICU stay ≥ 4 days (No): Success | ICU stay ≥ 4 days (No): Failure | Mechanical ventilation (Yes): Success | Mechanical ventilation (Yes): Failure | Mechanical ventilation (No): Success | Mechanical ventilation (No): Failure | Antibiotics (Yes): Success | Antibiotics (Yes): Failure | Antibiotics (No): Success | Antibiotics (No): Failure | CV Catheter (Yes): Success | CV Catheter (Yes): Failure | CV Catheter (No): Success | CV Catheter (No): Failure | TPN (Yes): Success | TPN (Yes): Failure | TPN (No): Success | TPN (No): Failure | Dialysis (Yes): Success | Dialysis (Yes): Failure | Dialysis (No): Success | Dialysis (No): Failure | Abdominal surgery (Yes): Success | Abdominal surgery (Yes): Failure | Abdominal surgery (No): Success | Abdominal surgery (No): Failure | Solid organ transplant (No): Success | Solid organ transplant (No): Failure | Renal insufficiency (Yes): Success | Renal insufficiency (Yes): Failure | Renal insufficiency (No): Success | Renal insufficiency (No): Failure | Chemotherapy (Yes): Success | Chemotherapy (Yes): Failure | Chemotherapy (No): Success | Chemotherapy (No): Failure | Pancreatitis (Yes): Success | Pancreatitis (Yes): Failure | Pancreatitis (No): Success | Pancreatitis (No): Failure | Systemic steroids/immunos (Yes): Success | Systemic steroids/immunos (Yes): Failure | Systemic steroids/immunos (No): Success | Systemic steroids/immunos (No): Failure | Neutropenic: Success | Neutropenic: Failure | Non-neutropenic: Success | Non-neutropenic: Failure | |
| Anidulafungin-Voriconazole | 12 | 20 | 9 | 3 | 13 | 20 | 8 | 3 | 19 | 20 | 2 | 3 | 18 | 20 | 3 | 3 | 5 | 8 | 16 | 15 | 1 | 6 | 20 | 17 | 8 | 11 | 13 | 12 | 21 | 23 | 1 | 6 | 20 | 17 | 1 | 0 | 20 | 23 | 2 | 3 | 19 | 20 | 5 | 7 | 16 | 16 | 2 | 1 | 15 | 14 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Global response at EOT was assessed for participants categorized with baseline risk factors (Yes or No status) for Intensive Care Unit (ICU) stay ≥ 4 days, mechanical ventilation, broad spectrum antibiotics (antibiotics), central venous (CV) catheter, total parental nutrition (TPN), dialysis, abdominal surgery, solid organ transplant, renal insufficiency, chemotherapy, pancreatitis, systemic steroids or immunosuppressives (Systemic steroids/immunos), neutropenic status, or elderly. (NCT00548262)
Timeframe: Baseline, EOT (up to Day 42)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICU stay ≥ 4 days (Yes): Success | ICU stay ≥ 4 days (Yes): Failure | ICU stay ≥ 4 days (No): Success | ICU stay ≥ 4 days (No): Failure | Mechanical ventilation (Yes): Success | Mechanical ventilation (Yes): Failure | Mechanical ventilation (No): Success | Mechanical ventilation (No): Failure | Antibiotics (Yes): Success | Antibiotics (Yes): Failure | Antibiotics (No): Success | Antibiotics (No): Failure | CV Catheter (Yes): Success | CV Catheter (Yes): Failure | CV Catheter (No): Success | CV Catheter (No): Failure | TPN (Yes): Success | TPN (Yes): Failure | TPN (No): Success | TPN (No): Failure | Dialysis (Yes): Success | Dialysis (Yes): Failure | Dialysis (No): Success | Dialysis (No): Failure | Abdominal surgery (Yes): Success | Abdominal surgery (Yes): Failure | Abdominal surgery (No): Success | Abdominal surgery (No): Failure | Solid organ transplant (No): Success | Solid organ transplant (No): Failure | Renal insufficiency (Yes): Success | Renal insufficiency (Yes): Failure | Renal insufficiency (No): Success | Renal insufficiency (No): Failure | Chemotherapy (Yes): Success | Chemotherapy (Yes): Failure | Chemotherapy (No): Success | Chemotherapy (No): Failure | Pancreatitis (Yes): Success | Pancreatitis (Yes): Failure | Pancreatitis (No): Success | Pancreatitis (No): Failure | Systemic steroids/immunos (Yes): Success | Systemic steroids/immunos (Yes): Failure | Systemic steroids/immunos (No): Success | Systemic steroids/immunos (No): Failure | Neutropenic: Success | Neutropenic: Failure | Non-neutropenic: Success | Non-neutropenic: Failure | |
| Anidulafungin-Voriconazole | 18 | 14 | 8 | 4 | 18 | 15 | 8 | 3 | 22 | 17 | 4 | 1 | 21 | 17 | 5 | 1 | 5 | 8 | 21 | 10 | 3 | 4 | 23 | 14 | 11 | 8 | 15 | 10 | 26 | 18 | 3 | 4 | 23 | 14 | 1 | 0 | 25 | 18 | 1 | 4 | 25 | 14 | 6 | 6 | 20 | 12 | 2 | 1 | 18 | 11 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at EIVT was assessed per the type of Candida species that was isolated at the baseline visit. (NCT00548262)
Timeframe: Baseline, EIVT (up to Day 42)
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candida albicans: Success | Candida albicans: Failure | Candida famata: Success | Candida famata: Failure | Candida glabrata: Success | Candida glabrata: Failure | Candida guilliermondii: Success | Candida guilliermondii: Failure | Candida krusei: Success | Candida krusei: Failure | Candida parapsilosis: Success | Candida parapsilosis: Failure | Candida pelliculosa: Success | Candida pelliculosa: Failure | Candida tropicalis: Success | Candida tropicalis: Failure | Unidentifiable: Success | Unidentifiable: Failure | |
| Anidulafungin-Voriconazole | 11 | 10 | 1 | 1 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 5 | 1 | 0 | 8 | 2 | 4 | 3 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at EOT was assessed per the type of Candida species that was isolated at the baseline visit. (NCT00548262)
Timeframe: Baseline, EOT (up to Day 42)
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candida albicans: Success | Candida albicans: Failure | Candida famata: Success | Candida famata: Failure | Candida glabrata: Success | Candida glabrata: Failure | Candida guilliermondii: Success | Candida guilliermondii: Failure | Candida krusei: Success | Candida krusei: Failure | Candida parapsilosis: Success | Candida parapsilosis: Failure | Candida pelliculosa: Success | Candida pelliculosa: Failure | Candida tropicalis: Success | Candida tropicalis: Failure | Unidentifiable: Success | Unidentifiable: Failure | |
| Anidulafungin-Voriconazole | 11 | 10 | 0 | 2 | 2 | 1 | 1 | 0 | 2 | 1 | 1 | 5 | 1 | 0 | 8 | 2 | 4 | 3 |
Global response based on assessments of Clinical Success or Failure and Microbiological Success or Failure. Categorized as global Success if both clinical and microbiological response=success; Failure defined as all other combinations. Global response at Week 2 Follow-up was assessed per the type of Candida species that was isolated at the baseline visit. (NCT00548262)
Timeframe: Baseline, Week 2 Follow-up
| Intervention | participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Candida albicans: Success | Candida albicans: Failure | Candida famata: Success | Candida famata: Failure | Candida glabrata: Success | Candida glabrata: Failure | Candida guilliermondii: Success | Candida guilliermondii: Failure | Candida krusei: Success | Candida krusei: Failure | Candida parapsilosis: Success | Candida parapsilosis: Failure | Candida pelliculosa: Success | Candida pelliculosa: Failure | Candida tropicalis: Success | Candida tropicalis: Failure | Unidentifiable: Success | Unidentifiable: Failure | |
| Anidulafungin-Voriconazole | 10 | 11 | 0 | 2 | 3 | 0 | 1 | 0 | 2 | 1 | 0 | 6 | 1 | 0 | 7 | 3 | 2 | 5 |
(NCT00548262)
Timeframe: Day 30
| Intervention | participants (Number) | |
|---|---|---|
| Alive | Dead | |
| Anidulafungin-Voriconazole | 25 | 19 |
"Death is attributable to Candidemia or Invasive Candidiasis if investigator recorded disease under study as cause of death. Candidemia (positive blood culture) or Invasive Cadidiasis (yeast cells in histopathological or cytopathological exam). Week 6 Follow-up visit conducted by phone." (NCT00548262)
Timeframe: Baseline to Week 6 Follow-up
| Intervention | participants (Number) | |
|---|---|---|
| Attributable death (Yes) | Attributable death (No) | |
| Anidulafungin-Voriconazole | 4 | 19 |
Analysis of length of hospital stay based on Kaplan-Meier survival techniques. (NCT00496197)
Timeframe: Baseline up to 6 Week Follow-up (EOS)
| Intervention | days (Mean) |
|---|---|
| Anidulafungin | 18.4 |
Analysis of length of hospital stay based on Kaplan-Meier survival techniques. (NCT00496197)
Timeframe: Baseline up to End of Intravenous treatment (Day 5 up to Day 28)
| Intervention | days (Mean) |
|---|---|
| Anidulafungin | 8.9 |
Overall therapy includes Intravenous and Oral therapy. Participants were to receive at least 5 days and a maximum of 28 days of IV anidulafungin. After that, participants could continue treatment with oral fluconazole or voriconazole for at least 14 days from the day of last positive culture. (NCT00496197)
Timeframe: Baseline up to End of Treatment (Day 5 up to Day 42)
| Intervention | days (Mean) |
|---|---|
| Anidulafungin | 14.1 |
(NCT00496197)
Timeframe: Baseline up to Week 6 Follow-up (EOS) or 30 days after last dose of study drug (whichever was later)
| Intervention | participants (Number) |
|---|---|
| Anidulafungin | 65 |
Participants with a negative culture on Day 1 were not included in the analysis. For participants with a positive culture on Day 1, the first day on which there was a negative culture was determined and then compared to the result of the next culture. If the next culture was also negative, or the next culture was positive but the interval between the 2 cultures was > 3 days, the earlier of the 2 cultures was the day of first negative blood culture. If next culture was positive and taken within 3 days of the previous culture, the process was repeated with the next negative blood culture. (NCT00496197)
Timeframe: Baseline (Day 1) up to Week 6 Follow-up (EOS)
| Intervention | days (Number) |
|---|---|
| Anidulafungin | 3.0000 |
Measured as time to dischargeable (medically dischargeable status) and as time to discharge (actual discharge). Analysis of length of hospital stay based on Kaplan-Meier survival techniques. (NCT00496197)
Timeframe: Baseline up to 6 Week Follow-up (EOS)
| Intervention | days (Mean) | |
|---|---|---|
| Time to dischargeable | Time to discharge | |
| Anidulafungin | 27.3 | 27.1 |
Cause of death (includes all-cause and attributable to Candida infection) reported based on death due to Serious Adverse Events (SAEs). SAEs are any untoward medical occurrence at any dose that results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, results in congenital anomaly or birth defect. Participants may be counted with > 1 cause of death if multiple causes were present. (NCT00496197)
Timeframe: Baseline up to Week 6 Follow-up (EOS) or 30 days after last dose of study drug (whichever was later)
| Intervention | participants (Number) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute myocardial infarction | Acute respiratory failure | Anastomotic complication | Ascites | Atrial flutter | Bile duct cancer | Brain oedema | Cardiac arrest | Cardiac failure congestive | Cardio-respiratory arrest | Chronic hepatic failure | Coagulopathy | Colon cancer | Convulsion | Deep vein thrombosis | Diabetes mellitus | Disease progression | Dyspnoea | Electromechanical dissociation | Endocarditis | Endotracheal intubation | Fungaemia | Gastrointestinal haemorrhage | Gastrointestinal ischaemia | General physical health deterioration | Haemorrhage | Haemorrhage intracranial | Hepatic failure | Hypoglycaemia | Hyponatraemia | Hypotension | Infection | Ischaemic cardiomyopathy | Liver function test abnormal | Lymphoma | Mental status changes | Metastatic gastric cancer | Multi-organ disorder | Multi-organ failure | Multiple myeloma | Multiple sclerosis relapse | Myocardial infarction | Neoplasm malignant | Peritonitis | Peritonitis bacterial | Pneumonia | Pneumothorax | Pulmonary embolism | Pulmonary haemorrhage | Renal failure | Renal failure acute | Renal failure chronic | Respiratory arrest | Respiratory distress | Respiratory failure | Sepsis | Septic shock | Systemic candida | Thrombocytopenia | Wound dehiscence | |
| Anidulafungin | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 5 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 8 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 1 | 5 | 1 | 1 | 3 | 2 | 6 | 12 | 7 | 1 | 1 | 1 |
Clinical Success=Cure: resolution of Candida s/s or Improvement: significant but incomplete resolution of s/s; Clinical Failure: at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida. (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Cure | Improvement | Failure | |
| Anidulafungin | 159 | 57 | 16 |
Clinical Success=Cure: resolution of Candida s/s or Improvement: significant but incomplete resolution of s/s; Clinical Failure: at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida. (NCT00496197)
Timeframe: End of Treatment (Day 5 up to Day 42)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Cure | Improvement | Failure | |
| Anidulafungin | 160 | 14 | 13 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 208 | 27 |
Success: Clinical response=Cure (no signs, symptoms [s/s] of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (follow up [f/u] culture negative) or Presumed Eradication (f/u culture not available [n/a] and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida species [spp]) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: End of Treatment (Day 5 up to Day 42)
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 170 | 33 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 119 | 20 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: End of Treatment (Day 5 up to Day 42)
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 99 | 21 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: Week 2 Follow-up
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 89 | 27 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: Week 6 Follow-up (EOS)
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 75 | 36 |
Microbiological Success=Eradication: negative culture for baseline Candida spp or Presumed Eradication: f/u culture n/a and clinical outcome defined as success (cure or improvement); Microbiological Failure=Persistence: positive culture for at least 1 baseline Candida spp or Presumed Persistence: f/u culture n/a and clinical outcome defined as failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida). (NCT00496197)
Timeframe: End of Intravenous treatment (Day 5 up to Day 28)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Eradication | Presumed eradication | Persistence | Presumed persistence | |
| Anidulafungin | 163 | 61 | 15 | 3 |
Microbiological Success=Eradication: negative culture for baseline Candida spp or Presumed Eradication: f/u culture n/a and clinical outcome defined as success (cure or improvement); Microbiological Failure=Persistence: positive culture for at least 1 baseline Candida spp or Presumed Persistence: f/u culture n/a and clinical outcome defined as failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida). (NCT00496197)
Timeframe: End of Treatment (Day 5 up to Day 42)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Eradication | Presumed eradication | Persistence | Presumed persistence | |
| Anidulafungin | 124 | 59 | 6 | 3 |
AEs are any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAEs are any untoward medical occurrence at any dose that results in death, is life threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability or incapacity, results in congenital anomaly or birth defect. (NCT00496197)
Timeframe: Baseline up to Week 6 Follow-up (EOS) or 30 days after last dose of study drug (whichever was later)
| Intervention | participants (Number) | |
|---|---|---|
| Non-serious Adverse Events | Serious Adverse Events | |
| Anidulafungin | 216 | 134 |
Clinical Success=Cure: resolution of Candida s/s or Improvement: significant but incomplete resolution of s/s; Clinical Failure: at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida. (NCT00496197)
Timeframe: Week 2 follow-up
| Intervention | participants (Number) | ||
|---|---|---|---|
| Cure | Improvement | Failure | |
| Anidulafungin | 155 | 9 | 9 |
Clinical Success=Cure: resolution of Candida s/s or Improvement: significant but incomplete resolution of s/s; Clinical Failure: at least 3 doses Anidulafungin with no significant improvement in s/s or death due to Candida. (NCT00496197)
Timeframe: Week 6 follow-up (EOS)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Cure | Improvement | Failure | |
| Anidulafungin | 138 | 8 | 10 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: Week 2 Follow-up
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 148 | 46 |
Success: Clinical response=Cure (s/s of Candida) or Improvement (significant, incomplete resolution of s/s) and Microbiological response=Eradication (f/u culture negative) or Presumed Eradication (f/u culture n/a and response of clinical success). Failure: Clinical response=Failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida) and Microbiological response=Persistence (positive culture for ≥1 baseline Candida spp) or Presumed Persistence (f/u culture n/a and clinical outcome= failure). (NCT00496197)
Timeframe: Week 6 Follow-up (EOS)
| Intervention | participants (Number) | |
|---|---|---|
| Success (Cure or Improvement) | Failure | |
| Anidulafungin | 131 | 56 |
Microbiological Success=Eradication: negative culture for baseline Candida spp or Presumed Eradication: f/u culture n/a and clinical outcome defined as success (cure or improvement); Microbiological Failure=Persistence: positive culture for at least 1 baseline Candida spp or Presumed Persistence: f/u culture n/a and clinical outcome defined as failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida). (NCT00496197)
Timeframe: Week 2 Follow-up
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Eradication | Presumed eradication | Persistence | Presumed persistence | |
| Anidulafungin | 30 | 135 | 3 | 5 |
Microbiological Success=Eradication: negative culture for baseline Candida spp or Presumed Eradication: f/u culture n/a and clinical outcome defined as success (cure or improvement); Microbiological Failure=Persistence: positive culture for at least 1 baseline Candida spp or Presumed Persistence: f/u culture n/a and clinical outcome defined as failure (≥3 doses Anidulafungin with no significant improvement in s/s or death due to Candida). (NCT00496197)
Timeframe: Week 6 Follow-up (EOS)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Eradication | Presumed eradication | Persistence | Presumed persistence | |
| Anidulafungin | 12 | 134 | 2 | 8 |
Number of subjects with clinician assessed global response of success; defined as cure (resolution of signs and symptoms of Candida infection) or improvement (significant but incomplete resolution of signs and symptoms of Candida infection) on the clinical response in conjunction with eradication (follow up negative culture result for Candida species [spp]) or presumed eradication (follow up culture was not available and clinical outcome defined as success) on the microbiological response. (NCT00537329)
Timeframe: End of treatment (EOT) = Day 5 up to Day 42
| Intervention | participants (Number) |
|---|---|
| Anidulafungin | 31 |
Absolute values for β-D-glucan (range 0 to 6000 picograms per milliliter [pg/mL]) summarized at all timeframe endpoints by subject's at end of all treatment clinical response status of success (Success at EOT) or failure (Failure at EOT) and as combined status of all subjects (All at EOT). Success: cure (resolution of signs and symptoms of Candida infection) or improvement (significant but incomplete resolution of signs and symptoms); failure: no significant improvement in signs and symptoms or death due to Candida infection; subjects must have received at least 3 doses of anidulafungin. (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)
| Intervention | pg/mL (Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Success at EOT: baseline β-D-glucan (n=30) | Failure at EOT: baseline β-D-glucan (n=10) | All at EOT: baseline β-D-glucan (n=40) | Success at EOT: Day 3 β-D-glucan (n=32) | Failure at EOT: Day 3 β-D-glucan (n=4) | All at EOT: Day 3 β-D-glucan (n=36) | Success at EOT: Day 5 β-D-glucan (n=29) | Failure at EOT: Day 5 β-D-glucan (n=6) | All at EOT: Day 5 β-D-glucan (n=35) | Success at EOT: Day 7 β-D-glucan (n=24) | Failure at EOT: Day 7 β-D-glucan (n=4) | All at EOT: Day 7 β-D-glucan (n=28) | Success at EOT: EOT β-D-glucan (n=28) | Failure at EOT: EOT β-D-glucan (n=3) | All at EOT: EOT β-D-glucan (n=31) | |
| Anidulafungin | 1095.8 | 1447.9 | 1183.9 | 1132.0 | 2753.3 | 1312.1 | 1140.5 | 2443.8 | 1363.9 | 1190.8 | 3140.8 | 1469.4 | 1018.9 | 2917.7 | 1202.7 |
Absolute values for β-D-glucan (range 0 to 6000 pg/mL) summarized at timeframe endpoints by subject's at end of all treatment microbiological response status of Success at EOT or Failure at EOT and as combined status of All at EOT. Success: eradication (follow up negative culture for Candida spp) or presumed eradication (follow up culture was not available and clinical outcome defined as success); failure: persistence (follow up culture was positive for at least 1 baseline Candida spp) or presumed persistence (follow up culture was not available and clinical outcome was defined as failure). (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)
| Intervention | pg/mL (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Success at EOT: baseline β-D-glucan (n=32) | Failure at EOT: baseline β-D-glucan (n=8) | All at EOT: baseline β-D-glucan (n=40) | Success at EOT: Day 3 β-D-glucan (n=32) | Failure at EOT: Day 3 β-D-glucan (n=4) | All at EOT: Day 3 β-D-glucan (n=36) | Success at EOT: Day 5 β-D-glucan (n=29) | Failure at EOT: Day 5 β-D-glucan (n=6) | All at EOT: Day 5 β-D-glucan (n=35) | Success at EOT: Day 7 β-D-glucan (n=24) | Failure at EOT: Day 7 β-D-glucan (n=4) | All at EOT: Day 7 β-D-glucan (n=28) | Success at EOT: EOT β-D-glucan (n=31) | All at EOT: EOT β-D-glucan (n=31) | |
| Anidulafungin | 1219.7 | 1040.4 | 1183.9 | 1349.0 | 1017.4 | 1312.1 | 1444.3 | 975.3 | 1363.9 | 1527.2 | 1122.3 | 1469.4 | 1202.7 | 1202.7 |
Change from baseline for β-D-glucan (range 0 to 6000 pg/mL) summarized at endpoints by subject's at end of all treatment clinical response status of Success at EOT or Failure at EOT and as combined status of All at EOT. Success=cure (resolution of signs, symptoms of Candida infection) or improvement (significant but incomplete resolution of signs, symptoms); failure=no significant improvement or death due to Candida infection; subject must have received at least 3 doses of anidulafungin. Percent change calculated as ([mean value of β-D-glucan at observation-baseline value]/baseline value*100). (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)
| Intervention | percent change (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Success at EOT: Day 3 β-D-glucan (n=30) | Failure at EOT: Day 3 β-D-glucan (n=4) | All at EOT: Day 3 β-D-glucan (n=34) | Success at EOT: Day 5 β-D-glucan (n=27) | Failure at EOT: Day 5 β-D-glucan (n=6) | All at EOT: Day 5 β-D-glucan (n=33) | Success at EOT: Day 7 β-D-glucan (n=23) | Failure at EOT: Day 7 β-D-glucan (n=4) | All at EOT: Day 7 β-D-glucan (n=27) | Success at EOT: EOT β-D-glucan (n=27) | Failure at EOT: EOT β-D-glucan (n=3) | All at EOT: EOT β-D-glucan (n=30) | |
| Anidulafungin | -0.4 | -11.0 | -1.7 | -1.0 | 1.3 | -0.6 | 4.3 | 4.5 | 4.3 | 7.0 | 14.0 | 7.7 |
Change from baseline in β-D-glucan (range 0 to 6000 pg/mL) summarized at endpoints and by subject's EOT microbiological response status of Success at EOT or Failure at EOT and as combined status of All at EOT. Success=eradication (negative culture Candida spp or presumed eradication (culture not available, clinical outcome defined as success); failure=persistence (culture positive for at least 1 baseline Candida spp) or presumed persistence (culture not available, clinical outcome defined as failure). Percent change=([mean value of β-D-glucan at observation-baseline value]/baseline value*100). (NCT00537329)
Timeframe: Baseline, Day 3, Day 5, Day 7, EOT (Day 5 up to Day 42)
| Intervention | percent change (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Success at EOT: Day 3 β-D-glucan (n=30) | Failure at EOT: Day 3 β-D-glucan (n=4) | All at EOT: Day 3 β-D-glucan (n=34) | Success at EOT: Day 5 β-D-glucan (n=27) | Failure at EOT: Day 5 β-D-glucan (n=6) | All at EOT: Day 5 β-D-glucan (n=33) | Success at EOT: Day 7 β-D-glucan (n=23) | Failure at EOT: Day 7 β-D-glucan (n=4) | All at EOT: Day 7 β-D-glucan (n=27) | Success at EOT: EOT β-D-glucan (n=30) | All at EOT: Day 7 β-D-glucan (n=30) | |
| Anidulafungin | 0.0 | -14.3 | -1.7 | 0.4 | -5.2 | -0.6 | 5.6 | -3.0 | 4.3 | 7.7 | 7.7 |
Number of subjects with clinician assessed clinical response (CR) of success. Defined as cure or improvement (cure/improvement): cure=resolution of signs and symptoms of Candida infection; improvement=significant but incomplete resolution of signs and symptoms of Candida infection on the clinical response. (NCT00537329)
Timeframe: EOIT, EOT (Day 5 up to Day 42), 2 Wks post EOT, 6 Wks post EOT, 12 Wks post baseline
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EOIT: success (cure/improvement) | EOIT: cure | EOIT: improvement | EOT: success (cure/improvement) | EOT: cure | EOT: improvement | 2 Wks post EOT: success (cure/improvement) | 2 Wks post EOT: cure | 2 Wks post EOT: improvement | 6 Wks post EOT: success (cure/improvement) | 6 Wks post EOT: cure | 6 Wks post EOT: improvement | 12 Wks post baseline: success (cure/improvement) | 12 Wks post baseline: cure | 12 Wks post baseline: improvement | |
| Anidulafungin | 34 | 27 | 7 | 32 | 27 | 5 | 26 | 25 | 1 | 17 | 16 | 1 | 17 | 17 | 0 |
Number of subjects with clinician assessed global response of success. Defined as cure or improvement (cure/improvement): cure=resolution of signs and symptoms of Candida infection; improvement=significant but incomplete resolution of signs and symptoms of Candida infection on the clinical response in conjunction with eradication or presumed eradication (erad/presumed erad): erad=follow up negative culture result for Candida spp; presumed erad=follow up culture was not available and clinical outcome defined as success on the microbiological response. (NCT00537329)
Timeframe: End of intravenous treatment (EOIT), end of Week 2 after EOT (2 Wks post EOT), end of Week 6 after EOT (6 Wks post EOT), at end of 12 weeks after baseline (12 Wks post baseline)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| EOIT | 2 Wks post EOT | 6 Wks post EOT | 12 Wks post baseline | |
| Anidulafungin | 33 | 24 | 17 | 16 |
Number of subjects with clinician assessed global response of success at EOT (clinical=cure, improvement, microbiological=eradication, presumed eradication) in relation to subject subgroups (subject may be represented in >1 subgroup). Subgroups: Neutropenic status (absolute neutrophil count [ANC in cubic millimeters [cmm]); baseline pathogen; previous surgery (any surgery, abdominal surgery); organ transplantation (kidney, liver, heart); elderly; renal insufficiency (calculated creatinine clearance [CCC] in milliliters per minute [mL/min]); central venous catheter; receiving chemotherapy. (NCT00537329)
Timeframe: EOT (Day 5 up to Day 42)
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neutropenic status: ANC ≤ 500/cmm (n=2) | Neutropenic status: ANC >500/cmm (n=37) | Baseline pathogen: Candida albicans (n=14) | Baseline pathogen: Candida glabrata (n=6) | Baseline pathogen: Candida parapsilosis (n=4) | Baseline pathogen: Candida rugosa (n=1) | Baseline pathogen: Candida tropicalis (n=18) | Previous surgery: Any surgery (n=13) | Previous surgery: Abdominal surgery (n=8) | Elderly: Age ≥ 65 years (n=17) | Renal insufficiency (CCC < 30 mL/min) (n=11) | Use of Central venous catheter = Yes (n=21) | Receiving chemotherapy = Yes (n=7) | |
| Anidulafungin | 1 | 28 | 10 | 4 | 4 | 1 | 13 | 11 | 7 | 10 | 6 | 17 | 5 |
Number of subjects with clinician assessed microbiological response (MR) of success. Defined as eradication or presumed eradication (erad/presumed erad): erad=follow up negative culture result for Candida spp; presumed eradication=follow up culture was not available and clinical outcome defined as success on the microbiological response. (NCT00537329)
Timeframe: EOIT, EOT (Day 5 up to Day 42), 2 Wks post EOT, 6 Wks post EOT, 12 Wks post baseline
| Intervention | participants (Number) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EOIT: success (erad/presumed erad) | EOIT: erad | EOIT: presumed erad | EOT: success (erad/presumed erad) | EOT: erad | EOT: presumed erad | 2 Wks post EOT: success (erad/presumed erad) | 2 Wks post EOT: erad | 2 Wks post EOT: presumed erad | 6 Wks post EOT: success (erad/presumed erad) | 6 Wks post EOT: erad | 6 Wks post EOT: presumed erad | 12 Wks post baseline: success (erad/presumed erad) | 12 Wks post baseline: erad | 12 Wks post baseline: presumed erad | |
| Anidulafungin | 36 | 31 | 5 | 34 | 31 | 3 | 25 | 22 | 3 | 17 | 14 | 3 | 16 | 14 | 2 |
median duration of therapy with an echinocandin (caspofungin or micafungin) for persistent febrile neutropenia (FN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 10 |
| Micafungin Arm | 9 |
Median number of days patients were hospitalized during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 29 |
| Micafungin Arm | 28 |
Median number of days patients were neutropenic during the study period (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | days (Median) |
|---|---|
| Caspofungin Arm | 20 |
| Micafungin Arm | 17 |
a breakthrough invasive fungal disesase was defined as any fungal infection that was diagnosed > 3 days on or during therapy or within 7 days after completion of therapy with an echinocandin (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| No breakthrough IFD | Breakthrough IFD | |
| Caspofungin Arm | 133 | 16 |
| Micafungin Arm | 153 | 21 |
Overall favorable response was defined as achievement of successful treatment of baseline fungal infections, survival to hospital discharge, absence of breakthrough Ivasive fungal disese (IFD), and lack of advserse events (AE) attributable to treatment that led to discontinuation of echinocandin therapy. (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| Yes | No | |
| Caspofungin Arm | 122 | 27 |
| Micafungin Arm | 141 | 33 |
Defined as any advsere event directly attributable to echinocandin treatment that led to discontinuation of therapy or switch to alternative therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| No ADE | ADE which caused EC therapy discontinuation | |
| Caspofungin Arm | 146 | 3 |
| Micafungin Arm | 172 | 2 |
aspartate aminotransferase (AST) or alanine aminotransferase (ALT)> 5x the upper limit of normal (ULN) or total bilirubin > 3x the upper limit of normal (ULN) (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No LFT elevations | AST > 5x upper limit of normal | ALT > 5x upper limit of normal | Total Bilirubin >3x upper limit of normal | |
| Caspofungin Arm | 110 | 14 | 10 | 15 |
| Micafungin Arm | 132 | 15 | 9 | 18 |
We assessed all patients in the study cohort who dischaged from the hospital alive (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |
|---|---|---|
| Alive at hospital discharge | Died before hospitial discharge | |
| Caspofungin Arm | 137 | 12 |
| Micafungin Arm | 161 | 13 |
The description of the adverse event that resulted in discontinuation of echinocandin (EC) therapy (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| No Adverse Event requiring EC discontinuation | Rash | Liver function Test (LFT) increase | Anaphylaxis | |
| Caspofungin Arm | 146 | 2 | 0 | 1 |
| Micafungin Arm | 172 | 1 | 1 | 0 |
Possible or proven baseline invasive fungal disease were defined as were diagnosed within the 2 days of initiating echinocandin therapy for persistent febrile neutropenia (NCT00723073)
Timeframe: 11/1/2005 - 10/31/2007
| Intervention | participants (Number) | ||
|---|---|---|---|
| No Baseline IFD | Successfully treated baseline IFD | Unsuccessfully treated baseline IFD | |
| Caspofungin Arm | 146 | 2 | 1 |
| Micafungin Arm | 168 | 4 | 2 |
26 reviews available for fluconazole and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fl | 2021 |
Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Fluconazole; Humans; Liposomes; Mycoses; Neoplasms | 2014 |
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
Topics: Administration, Oral; Amphotericin B; Antifungal Agents; Confidence Intervals; Fluconazole; Humans; | 2014 |
[Fungal infections in oncohematology: the role of prophylaxis].
Topics: Antifungal Agents; Antineoplastic Agents; Fever; Fluconazole; Hematologic Neoplasms; Humans; Mycoses | 2010 |
Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Child; Child, | 2012 |
Voriconazole versus amphotericin B in cancer patients with neutropenia.
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Fluconazole; Humans; Liposomes; Mycoses; Neoplasms | 2006 |
Broad-spectrum antifungal prophylaxis in patients with cancer at high risk for invasive mold infections: point.
Topics: Antifungal Agents; Fluconazole; Humans; Immunocompromised Host; Itraconazole; Mycoses; Myelodysplast | 2008 |
[Prophylaxis against mycoses in neutropenic patients].
Topics: Amphotericin B; Antifungal Agents; Aspergillosis; Bone Marrow Transplantation; Candidiasis; Fluconaz | 1994 |
[Therapy of systemic candidiasis].
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Burns; Candidiasis; Flucon | 1994 |
[Prophylaxis and therapy of fungal infections in oncology].
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Incidence; Mycoses; Neoplasms; Triazoles | 1995 |
Infections due to resistant Candida species in patients with cancer who are receiving chemotherapy.
Topics: Antifungal Agents; Candida; Candidiasis; Drug Resistance, Microbial; Fluconazole; Humans; Itraconazo | 1994 |
Diagnosis and treatment of invasive fungal infections in cancer patients.
Topics: Amphotericin B; Aspergillosis; Fluconazole; Humans; Itraconazole; Lung Diseases, Fungal; Mycoses; Ne | 1993 |
Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Animals; Antifungal Agent | 1995 |
Systemic fungal infections: major problems in cancer patients.
Topics: Antifungal Agents; Antineoplastic Agents; Bone Marrow Transplantation; Fluconazole; Humans; Immunoco | 1994 |
Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Itraconazole; Ketoconazole; Miconazole; Myco | 1997 |
[Fluconazole (Diflucan): its clinical spectrum and development].
Topics: Adult; AIDS-Related Opportunistic Infections; Antifungal Agents; Candidiasis, Oral; Child; Cryptococ | 1997 |
Antifungal treatment in patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Drug Therapy, Combination; Fluconazole; Humans; Itraconazole; Myc | 1997 |
Invasive infections due to Clavispora lusitaniae.
Topics: Adult; Amphotericin B; Antifungal Agents; Child, Preschool; Fluconazole; Fungemia; Humans; Meningiti | 1999 |
Nosocomial Candida krusei fungemia in cancer patients: report of 10 cases and review.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Candida; Candidiasis; Cross Infection; Female; Fluco | 1999 |
Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.
Topics: Amphotericin B; Antifungal Agents; Confidence Intervals; Fluconazole; Humans; Mycoses; Neoplasms; Ne | 2000 |
Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials.
Topics: Administration, Oral; Antifungal Agents; Antineoplastic Agents; Fluconazole; Humans; Mycoses; Neopla | 2000 |
[Prevention of fungal infections in children and adolescents with cancer].
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Amphotericin B; Anemia, Aplastic; Antifungal A | 2001 |
Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients.
Topics: Amphotericin B; Antifungal Agents; Confidence Intervals; Fluconazole; Humans; Mycoses; Neoplasms; Ne | 2002 |
The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia.
Topics: Amphotericin B; Bone Marrow Transplantation; Candidiasis; Disease Susceptibility; Double-Blind Metho | 1992 |
New drugs for infections in patients with cancer.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Bacterial Infections; Cytomegalovirus Infections; Fluc | 1992 |
22 trials available for fluconazole and Benign Neoplasms
| Article | Year |
|---|---|
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Fluconazole; Humans; Neoplasms; Vor | 2023 |
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Fluconazole; Humans; Neoplasms; Vor | 2023 |
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Fluconazole; Humans; Neoplasms; Vor | 2023 |
A phase 1, open-label, randomized drug-drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies.
Topics: Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Fluconazole; Humans; Neoplasms; Vor | 2023 |
Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Topics: Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dru | 2023 |
Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Ca | 2019 |
[Modern antifungals in therapy of nosocomial mycosis in oncologic patients].
Topics: Antifungal Agents; Candida; Candidiasis, Invasive; Cross Infection; Drug Resistance, Fungal; Female; | 2011 |
An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Oral; F | 2004 |
Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant.
Topics: Adolescent; Adult; Antifungal Agents; Area Under Curve; Bone Marrow Transplantation; Chemoprevention | 2005 |
Prophylactic use of fluconazole in neutropenic cancer patients.
Topics: Adolescent; Adult; Aged; Female; Fluconazole; Humans; Male; Middle Aged; Mycoses; Neoplasms; Neutrop | 1995 |
Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections.
Topics: Adolescent; Adult; Aged; Aspergillus; Dose-Response Relationship, Drug; Female; Fluconazole; Fusariu | 1995 |
Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. The Multicenter Fluconazole Study Group.
Topics: Administration, Oral; Adolescent; Candidiasis, Oral; Child; Child, Preschool; Double-Blind Method; D | 1995 |
A multicentre study of fluconazole versus oral polyenes in the prevention of fungal infection in children with hematological or oncological malignancies. Multicentre Study Group.
Topics: Administration, Oral; Adolescent; Amphotericin B; Candida; Child; Child, Preschool; Female; Fluconaz | 1994 |
[Empiric therapy with fluconazole in granulocytopenic patients with carcinoma or leukemia].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Bacterial Infections; | 1994 |
Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.
Topics: Adult; Candida; Candidiasis, Oral; Esophageal Diseases; Female; Fluconazole; Humans; Male; Middle Ag | 1994 |
Fluconazole treatment of children with severe fungal infections not treatable with conventional agents.
Topics: Adolescent; Age Factors; AIDS-Related Opportunistic Infections; Body Weight; Candida; Candidiasis; C | 1994 |
Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.
Topics: Acyclovir; Adult; Bacteremia; Bone Marrow Transplantation; Female; Fever; Fluconazole; Gram-Positive | 1994 |
Fluconazole versus itraconazole in therapy of oropharyngeal candidiasis in cancer patients: a prospective comparative randomized trial.
Topics: Adult; Aged; Antifungal Agents; Candidiasis, Oral; Fluconazole; Humans; Itraconazole; Middle Aged; N | 1995 |
Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trial.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amphotericin B; Antifungal Agents; Child; Child, Preschool | 1996 |
Fluconazole versus nystatin in the prevention of candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer.
Topics: Adolescent; Antifungal Agents; Antineoplastic Agents; Candida albicans; Candidiasis; Child; Child, P | 1997 |
Bacteremia and fungemia in pediatric versus adult cancer patients after chemotherapy: comparison of etiology, risk factors and outcome.
Topics: Adult; Analysis of Variance; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; A | 1998 |
A randomized comparison of fluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Female; Fever; Fluconazole; Humans; Male; Midd | 1998 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer.
Topics: Amphotericin B; Antifungal Agents; Cause of Death; Female; Fever; Fluconazole; Humans; Infusions, In | 2000 |
The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia.
Topics: Amphotericin B; Bone Marrow Transplantation; Candidiasis; Disease Susceptibility; Double-Blind Metho | 1992 |
Prophylaxis of candidiasis in cancer patients.
Topics: Adolescent; Adult; Aged; Candidiasis, Oral; Double-Blind Method; Female; Fluconazole; Humans; Male; | 1990 |
71 other studies available for fluconazole and Benign Neoplasms
| Article | Year |
|---|---|
Design, synthesis, synergistic antimicrobial activity and cytotoxicity of 4-aryl substituted 3,4-dihydropyrimidinones of curcumin.
Topics: Anti-Infective Agents; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Curcumin; Drug Design | 2012 |
Tetrazolylmethyl quinolines: Design, docking studies, synthesis, anticancer and antifungal analyses.
Topics: Antifungal Agents; Antineoplastic Agents; Candida albicans; Cell Proliferation; Crystallography, X-R | 2017 |
Synthesis of Hemiprotonic Phenanthroline-Phenanthroline
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antineoplastic Agents; Apo | 2022 |
The evaluation of the overexpression of the ERG-11, MDR-1, CDR-1, and CDR-2 genes in fluconazole-resistant Candida albicans isolated from Ahvazian cancer patients with oral candidiasis.
Topics: Antifungal Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Candida albicans; Candid | 2022 |
Identification and susceptibility testing of oral candidiasis in advanced cancer patients.
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidiasis, Oral; Drug | 2023 |
A 3-year study of
Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Drug Resistance, | 2023 |
Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
Topics: Anti-Bacterial Agents; Bayes Theorem; Child; Clindamycin; Critical Illness; Fluconazole; Humans; Lin | 2023 |
Alarming Increase of Azole-Resistant Candida Causing Blood Stream Infections in Oncology Patients in Egypt.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Candidemia; Candidiasis; Drug Resistance, Fung | 2023 |
Prevalence and susceptibility profile of Candida spp. isolated from patients in cancer therapy.
Topics: Amphotericin B; Antifungal Agents; Candida; Drug Resistance, Fungal; Female; Fluconazole; Humans; Ma | 2020 |
Impact of antifungal stewardship interventions on the susceptibility of colonized Candida species in pediatric patients with malignancy.
Topics: Adolescent; Amphotericin B; Antifungal Agents; Antimicrobial Stewardship; Candida; Caspofungin; Chil | 2021 |
The risk and clinical outcome of candidemia depending on underlying malignancy.
Topics: Adult; Aged; Antifungal Agents; Candida; Candidemia; Critical Illness; Female; Fluconazole; Humans; | 2017 |
Initial Treatment of Cancer Patients with Fluconazole-Susceptible Dose-Dependent Candida glabrata Fungemia: Better Outcome with an Echinocandin or Polyene Compared to an Azole?
Topics: Amphotericin B; Antifungal Agents; Azoles; Candida glabrata; Candidemia; Drug Resistance, Fungal; Ec | 2017 |
Mortality associated with candidemia in non-neutropenic cancer patients is not less compared to a neutropenic cohort of cancer patients.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidemia; Child; Child, Preschool; Cohort Stu | 2017 |
Candida infanticola and Candida spencermartinsiae yeasts: Possible emerging species in cancer patients.
Topics: Adolescent; Antifungal Agents; Candida; Candidiasis; Caspofungin; Child, Preschool; Echinocandins; F | 2018 |
Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis, Oral; Female; F | 2018 |
Comparison of the clinical risk factors between Candida albicans and Candida non-albicans species for bloodstream infection.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Candida; Candida albicans; Candid | 2014 |
Predictors and outcomes of Candida bloodstream infection: eight-year surveillance, western Saudi Arabia.
Topics: Adolescent; Adult; Antifungal Agents; Candida; Candida albicans; Candidemia; Candidiasis; Child; Chi | 2014 |
[Bronchoscopy in two cases of hemoptysis of difficult diagnostic interpretation (varices of the trachea associated with zonal bronchiectasis; malignant tumor of the bronchi)].
Topics: Bronchi; Bronchiectasis; Bronchoscopy; Fluconazole; Hemoptysis; Humans; Neoplasms; Trachea; Varicose | 1950 |
Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today.
Topics: Antifungal Agents; Candidiasis; Female; Fluconazole; Humans; Male; Neoplasms | 2014 |
Insufficient fluconazole exposure in pediatric cancer patients and the need for therapeutic drug monitoring in critically ill children.
Topics: Adolescent; Antifungal Agents; Candidiasis; Child; Child, Preschool; Critical Illness; Drug Monitori | 2014 |
Epidemiology and prognostic factors of candidemia in elderly patients.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Candida tropicalis; Candidemia; Comorbidity; Diabetes Me | 2015 |
Antifungal prophylaxis with posaconazole vs. fluconazole or itraconazole in pediatric patients with neutropenia.
Topics: Adolescent; Antifungal Agents; Chemoprevention; Child; Child, Preschool; Cohort Studies; Drug-Relate | 2015 |
Seven days in medicine: 2-8 January.
Topics: Abortion, Spontaneous; Alcoholic Beverages; Anti-Bacterial Agents; Antifungal Agents; Cardiomyopathi | 2016 |
Single-Dose Fluconazole Therapy for Oral Thrush in Hospice and Palliative Medicine Patients.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Candidiasis, Oral; Female; Fluconazole; Hospice C | 2017 |
Coccidioidomycosis in Patients with Selected Solid Organ Cancers: A Case Series and Review of Medical Literature.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Arizona; Coccidioidomycosis; Endemic Diseases; Fe | 2016 |
Not just little adults: candidemia epidemiology, molecular characterization, and antifungal susceptibility in neonatal and pediatric patients.
Topics: Adult; Amphotericin B; Antifungal Agents; Australia; Candida albicans; Candidiasis; Child; Child, Pr | 2009 |
Potential pharmacokinetic interactions affecting antitumor drug disposition in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Comorbidity; Cytochr | 2009 |
Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis; Drug Resistance | 2010 |
Fluconazole susceptibility and genotypic heterogeneity of oral Candida albicans colonies from the patients with cancer receiving chemotherapy in China.
Topics: Adult; Aged; Antifungal Agents; Candida albicans; Candida glabrata; Candidiasis, Oral; China; DNA, F | 2009 |
Posaconazole versus fluconazole or itraconazole for prevention of invasive fungal infections in patients undergoing intensive cytotoxic therapy for acute myeloid leukemia or myelodysplasia: a cost effectiveness analysis.
Topics: Antifungal Agents; Antineoplastic Agents; Canada; Cost Savings; Cost-Benefit Analysis; Decision Supp | 2011 |
Multilocus sequence typing of serial Candida albicans isolates from children with cancer, children with cystic fibrosis and healthy controls.
Topics: Adenoids; Adolescent; Antifungal Agents; Candida albicans; Candidiasis; Case-Control Studies; Child; | 2012 |
Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital.
Topics: Adolescent; Adult; Age Distribution; Aged; Antifungal Agents; Candidiasis; Causality; Comorbidity; C | 2002 |
Systematic discovery of multicomponent therapeutics.
Topics: Animals; Antifungal Agents; Automation; Candida albicans; Cell Division; Colony-Forming Units Assay; | 2003 |
ACTION OF TUMOR GROWTH AND TISSUE PRODUCTS ON THE ZONAL DISTRIBUTION OF LIVER GLYCOGEN IN RATS AND MICE.
Topics: Animals; Carcinoma; Carcinoma, Ehrlich Tumor; Fluconazole; Histocytochemistry; Liver Glycogen; Metab | 1963 |
ZONAL ELECTROPHORESIS OF THE SOLUBLE PROTEINS OF LIVER AND TUMOR IN AZO DYE CARCINOGENESIS.
Topics: Azo Compounds; Carcinogenesis; Carcinogens; Coloring Agents; Electrophoresis; Fluconazole; Freeze Dr | 1963 |
[The principle of anatomical zonal and field approach in removing malignant tumors].
Topics: Fluconazole; Humans; Neoplasms | 1960 |
High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Drug Resistance, Fungal; Female; Fluconazole; Hum | 2003 |
Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Candida; Candidiasis; | 2003 |
High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Candida; Candidiasis; Colony Count, Microbial; Do | 2004 |
In vitro susceptibility of Candida species isolated from cancer patients to some antifungal agents.
Topics: Amphotericin B; Antifungal Agents; Candida; Disease Susceptibility; Fluconazole; Flucytosine; Humans | 2004 |
Invasive Candida species infections: a 5 year population-based assessment.
Topics: Antifungal Agents; Canada; Candida; Candidiasis; Dose-Response Relationship, Drug; Drug Resistance, | 2005 |
Invasive fungal infections at The Norwegian Radium Hospital 1998-2003.
Topics: Adult; Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Cancer Care Facilities; Ca | 2005 |
Voriconazole susceptibility of yeasts isolated from the mouths of patients with advanced cancer.
Topics: Antifungal Agents; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity | 2005 |
Cryptococcosis in human immunodeficiency virus-negative patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Antifungal Agents; Cryptococcosis; Crypt | 2006 |
Risk factors for candidemia-related mortality at a medical center in central Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Amphotericin B; Anti-Bacterial Agents; APACHE; Candida; Candidiasis; | 2006 |
Epidemiological study of Candida infections in blood: susceptibilities of Candida spp. to antifungal agents, and clinical features associated with the candidemia.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Candida; Candidiasis; Child; Child, Preschool; Female; F | 2006 |
Fluconazole and itraconazole resistance of yeasts isolated from the bloodstream and catheters of hospitalized pediatric patients.
Topics: Adolescent; Antifungal Agents; Candida; Catheters, Indwelling; Child; Child, Preschool; Drug Resista | 2006 |
Epidemiology and outcome of Rhodotorula fungemia in a tertiary care hospital.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic | 2006 |
Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia.
Topics: Adult; Antifungal Agents; Candida albicans; Candidiasis; Cohort Studies; Female; Fever; Fluconazole; | 2006 |
Drug-drug interactions with systemic antifungals in clinical practice.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Creatinine; Cyclosporine; Drug Interactions; Female; | 2007 |
Antifungal susceptibility against yeasts isolated from pediatric oncology patients.
Topics: Adolescent; Adult; Antifungal Agents; Candida; Candidiasis; Catheterization, Central Venous; Child; | 2008 |
Deadly fungal infections spreading in cancer patients.
Topics: Antineoplastic Agents; Aspergillosis; Candidiasis; Fluconazole; Humans; Mycoses; Neoplasms; Opportun | 1995 |
Protein binding of itraconazole and fluconazole in patients with cancer.
Topics: Adult; Aged; Antifungal Agents; Blood Proteins; Breast Neoplasms; Colonic Neoplasms; Esophageal Neop | 1995 |
Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients.
Topics: Adult; Aged; Antifungal Agents; Cross Infection; Fluconazole; Humans; Male; Middle Aged; Neoplasms; | 1996 |
Resistance pattern of 2816 isolates isolated from 17631 blood cultures and etiology of bacteremia and fungemia in a single cancer institution.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Bacteremia; Cephal | 1997 |
Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.
Topics: Antifungal Agents; Azoles; Candida; Candida albicans; Drug Resistance, Microbial; Fluconazole; Human | 1998 |
Nosocomial breakthrough fungaemia during antifungal prophylaxis or empirical antifungal therapy in 41 cancer patients receiving antineoplastic chemotherapy: analysis of aetiology risk factors and outcome.
Topics: Amphotericin B; Antifungal Agents; Antineoplastic Agents; Cross Infection; Drug Resistance, Microbia | 1998 |
Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study.
Topics: Amikacin; Amphotericin B; Antibiotic Prophylaxis; Bacteremia; Bacterial Infections; Case-Control Stu | 1998 |
Candida parapsilosis fungemia in cancer patients--incidence, risk factors and outcome.
Topics: Adult; Amphotericin B; Antifungal Agents; Candida; Candida albicans; Candidiasis; Child; Female; Flu | 1998 |
Nosocomial candidaemias due to species other than Candida albicans in cancer patients. Aetiology, risk factors, and outcome of 45 episodes within 10 years in a single cancer institution.
Topics: Adrenal Cortex Hormones; Amphotericin B; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antifungal A | 1999 |
Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis.
Topics: Amphotericin B; Antifungal Agents; Fluconazole; Humans; Meta-Analysis as Topic; Mycoses; Neoplasms; | 1999 |
Infectious complications after autologous peripheral blood progenitor cell transplantation followed by G-CSF.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Antifungal Agents; Bone Marrow Transplantation; Fema | 1999 |
[Microbial analysis of clinical material taken from patients at the Oncology Center, Maria Skłodowkda-Curie Institute in Warsaw in 1997].
Topics: Bacterial Infections; Body Fluids; Candida albicans; Drug Resistance, Microbial; Fluconazole; Gram-N | 1999 |
Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Bone Marrow Transplantation; Candida; Candidiasis; D | 2001 |
Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients.
Topics: Adolescent; Adult; Amphotericin B; Antifungal Agents; Aspergillosis; Child; Female; Fluconazole; Hum | 2001 |
Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Topics: Adult; Antifungal Agents; Candida; Candida albicans; Child; Drug Resistance, Fungal; Fluconazole; Fu | 2000 |
The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer.
Topics: Amphotericin B; Antifungal Agents; APACHE; Bone Marrow Transplantation; Candida albicans; Candidiasi | 2002 |
Risk factors for breakthrough candidemia.
Topics: Amphotericin B; Anti-Bacterial Agents; Candidiasis; Fluconazole; Fungemia; Humans; Multivariate Anal | 2002 |
Fluconazole in the treatment of mycotic oropharyngeal stomatitis and esophagitis in neutropenic cancer patients.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Candidiasis, Oral; Drug Evaluation; Esophagitis; | 1991 |
Fungal infections in the cancer patient: clinical experience with fluconazole. Proceedings of a symposium. May 8, 1989, Washington, DC.
Topics: Fluconazole; Humans; Mycoses; Neoplasms | 1990 |
[Initial experience with fluconazole, a new triazole antimycotic agent, in oncology patients].
Topics: Adult; Female; Fluconazole; Humans; Immune Tolerance; Male; Mycoses; Neoplasms | 1990 |